COVER PAGE 
Official Title: 
Study ID: [REMOVED]  
Document Date: 01 June 2022 Zs>Ϯ͕WƌŽƐƉĞĐƚŝǀĞ͕ZĂŶĚŽŵŝǌĞĚ͕ŽƵďůĞͲďůŝŶĚ͕WůĂĐĞďŽͲ
ŽŶƚƌŽůůĞĚWŚĂƐĞϯ^ƚƵĚǇŽĨs'yͲϯϭϬϬĞůŝǀĞƌĞĚ/ŶƚƌĂŵƵƐĐƵůĂƌůǇ;/DͿĨŽůůŽǁĞĚďǇůĞĐƚƌŽƉŽƌĂƚŝŽŶǁŝƚŚ>>dZΡϱW^WĨŽƌƚŚĞdƌĞĂƚŵ ĞŶƚ
ŽĨ,WsͲϭϲĂŶĚͬŽƌ,WsͲϭϴƌĞůĂƚĞĚ,ŝŐŚ'ƌĂĚĞ^ƋƵĂŵŽƵƐ/ŶƚƌĂĞƉŝƚŚĞůŝĂů>ĞƐŝŽŶ;,^/>ͿϭŽĨƚŚĞĞƌǀŝǆ
REVEAL 2
(Randomized Evaluation of VGX-3100 and Electroporation  the Treatment of CervicAl 
HSIL)
HPV – 303
Sponsored by:
[CONTACT_360741], Inc.
U.S. IND #[ADDRESS_449779] #: 2018-004114-17
Version 4.1
01Jun2022
FINAL
REVEAL 2: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 
PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY 
[CONTACT_360742]™ 5PSP FOR THE TREATMENT OF HPV-16 
AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPI[INVESTIGATOR_343325] 
(HSIL) OF THE CERVIX
 -XQ  3URWRFRO _ 9970) _ 
$SSURYHGroporation for ration fo
)
V –[ZIP_CODE]
ponsored by: [CONTACT_360743]:
o Pharmaceutical armaceu
U.S. INU.S. IN
EudraEudra CTC
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449780]/Ethics Committee 
approval and informed consent, or as required by [CONTACT_31665]. Persons to whom this 
information is disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Inovio Pharmaceuticals. Any supplemental 
information added to this document is also confidential and proprietary information of Inovio Pharmaceuticals 
and must be kept in confidence in the same  manner as the contents of this document. -XQ  3URWRFRO _ 9970) _ 
$SSURYHG
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449781] been corrected in Protocol Version 4.1. 
1. The primary population to which the primary objective will be applied has been changed from 
“all subjects” to “subjects defined as biomarker-positive at baseline,” as identified by [CONTACT_282543] 
(miRNA) profiling performed from peripheral blood prior to dosing with VGX-3100 (Section 
6.10). This change has been made in order to define a population of patients in whom VGX-3100 
is more likely to be efficacious as defined by [CONTACT_39548]  n point of regression of cervical HSIL 
and clearance of HPV-16/18.  
2. The protocol has been revised to remove 4-quadrant biopsy as a potential procedure at Week 36
throughout the protocol. 
3. Stoppi[INVESTIGATOR_1869] (Criteria for Pausing of Study) added to Data Safety Monitoring Board Charter 
version 3.0. 
4. Update to acceptable contraception methods in Protocol Synopsis, Inclusion Criteria and Section 
4.1, Inclusion Criteria. A footnote has been added to clarify that use of condoms or condoms and spermicide are not acceptable forms of contraception.
5. Update to Table 1 : Schedule of Events and Sections 6.1.1 ,6.1.2 , and 6.4.12, Method of 
collection for cervical di e™ samples. Text was changed to update the method of collection of cervical digene™ samples from swabs to brushes at Screening, Day 0, Weeks 15, 28, and 36. 
6. Clarification of previous footnote “K” for Table 1: Schedule of Events. The footnote has been 
updated to indicate that a biopsy is only done at the Screening visits. 
7. Clarification of previous footnote “M” for Table 1 : Schedule of Events. The footnote has been 
updated to indicate that 4-quadrant biopsies will not be completed at Week 36. 
8. Clarification of Section 3 , Study Design and Endpoints and Section 8.7 , Randomization and 
Blinding. Text was included to clarify that the calculation of Body Mass Index (BMI) used to 
determine the stratification group at randomization should be performed using the Day 0 
measurements.
9. Clarification of Section 3 , Study Design and Endpoints. Text was included to clarify that the 
GHVLJQDWLRQ RI DJH FDWHJRU\  \HDUV YV  \HDUV XVHG WR GHWHUPLQH WKH VWUDWLILFDWLRQ JURXS
at randomization should be performed using the age at Day 0.
10. Clarification of the definition of Responder and Non-Responder in Section 3.1.4 , 8.5.1 and 
8.5.9 . The definition of non-responder was clarified to comprise subjects who undergo excision, 
or subjects whose cervix is biopsied, at any time between their initial dose of study drug and the Week 36 endpoint tissue collection. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGupop
im  pary end
adrant biopsy as a pnt biopsy as
tudy) ) added to Data dded to D
meth   Protocol ods in P
e has been added to been adde
form s of contraceptiof co
of Events and vents and Secti
gene™ s samplesamples . Tex
mpleses from swabs  from swabs tt
ious footnote “K” fo otnote “K” fo
e that a biopsy is onthat a biopsy is on
previous footnote “ ous footnote “
hat 44-quadra-q
3 Stud
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449782] be completed and negative within 60 days of Day 0. 
16. Clarification of  Section 6.1.1,  Screening Evaluations.  
 
17. Clarification of Section 6.1.2, Week 40 (Study Co lus on)  hole blood and serum samples are 
not obtained at Week 40 as i ndicated in Table 1, S e of Events. “Whole blood and serum 
for immunology” has been removed from the t t  
18. Clarification of Section 6.4.3, Height and Weigh    s clarified to include that height 
and weight should be collected at Screening and on Day 0, Weeks 4 and 12, and that the BMI at 
Day 0 will be used to determine BMI Stratum for randomization.
19. Clarification of Table 13 : Grading Scale for Injection Site Reactions in Protocol Section 6.9 , 
Assessment of Injection Site Reactions. Daily activity is defined for the Injection Site Reactions 
table.  
20. Clarification of Section 8.5 Planned rim Analysis. Language was added to this section to 
explain that group-level unblinding summaries and analyses may be produced once the primary endpoint data are com ed for all subjects, if deemed necessary.
21. Clarification of Section [IP_ADDRESS] , Vital Signs. The summary will be performed on the Safety 
population instead of the mITT population.
22. Clarification of Sectio  [ADDRESS_449783] be recorded on the CRF as stated in Section 6.12,
Concomitant Medications/Treatment. 
24. Clarification of Section 17 ,Appendices. Appendix A was updated to remove the procedure for 
collecting 4-quadrant biopsies at Week 36. 
Administrative Changes:
25. Administrative Change to Inclusion Criteria 5 in the Clinical Protocol Synopsis. The text has 
been updated to correspond with Inclusion Criteria 5 in Section 4.1, Inclusion Criteria. 
26. Administrative Change to Exclusion Criteria 3 in  Section 4.2, Exclusion Criteria. The text has 
been updated to correspond with Exclusion Criteria 3 in the Clinical Protocol Synopsis.  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGnclusision). Won). W
, Schedule of Evendule of E
e text.
Weight. The text w ht. The tex a
ning and andon Day 0, W on 
Stratum for randomtum for ran
Scale for Injection S for Inje
actions. Daily activit ns. Daily ac
.6,Plann  anned rim Inte
unblinding inding summariesumm
plete    d for all subject
tion8.[IP_ADDRESS], , Vital SV
d of the mITT populf the mITT popul
ection n95.9.3,Com
P reguleguatio
1So
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  5of 8727. Administrative Change to Section 5.3, CELLECTRA™ 5PSP device. A statement was added for 
informational purposes indicating that CELLECTRA™5PSP device is CE Marked in the 
European Union.
28. Administrative Change to Section 6.4.13, Colposcopy and Cervical Biopsies and Section 6.4.15 , 
Unscheduled Biopsies. The guidelines for Colposcopy and Surgical Excision is in Appendix A .
29. Administrative Change to Section 7.2, Adverse Events (AEs), and Section 7.11 , Procedure for 
Reporting Pregnancy During the Study. The additional information on pregnancy reporting is 
referenced there.  -XQ  3URWRFRO _ 9970) _ 
$SSURYHG
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449784] of the trial and approved or given favorable opi[INVESTIGATOR_151580].
The signature [CONTACT_114117] (PI) constitutes the PI’s approval of this protocol and 
provides the necessary assurances that this trial will be conducted in accordance with ICH/GCP and ISO guidelines, local legal and regulatory requirem s  nd all stipulations of the protocol.
_________________________________ _________________________
Principal Investigator [INVESTIGATOR_31325] (DDMMYYYY)      
__________________________________
Printed Name
[CONTACT_186772]: ___________________________
Site Name: _____________________________
EudraCT #: 2018-004114-17 -XQ  3URWRFRO _ 9970) _ 
$SSURYHGcondcon
ments, and ants, and
_______________
Date
________ __
______________ __________
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449785] ......................................................................... 22
1.3.2 CELLECTRA™ DEVICE DEVELOPMENT ....................................................... [ADDRESS_449786]  ....................................................................................... 28
3.1.1 PRIMARY ENDPOINT & EFFICACY ASSESSMENT ...................................... 28
3.1.2 HISTOLOGY ASSESSM NT ............................................................................... 28
3.1.3 VIROLOGIC ASS S ENT ................................................................................ 29
3.1.4 DEFINITION OF RESPONDER AND NON-RESPONDER ............................... 29
3.2 SECONDARY OBJECTIVES AND ENDPOINTS .................................................. 30
3.2.1 HISTOLOGY ASSESSMENT ............................................................................... 31
3.2.2 VIROLOGIC ASSESSMENT ................................................................................ 31
3.2.3 DEFINITION OF RESPONDER AND NON-RESPONDER ............................... 32
3.3 EXPLORATORY OBJECTIVES AND ENDPOINTS ............................................. 33
3.4 IMMUNOGENICITY ASSESSMENT ...................................................................... 34
3.5 SAFETY ASSESSMENT........................................................................................... 34 -XQ  3URWRFRO _ 9970) _ 
$SSURYHGENTNT ..... ...
......................... .............
 .............................................
............................................
............................. ............
EATMENT MENT .......... 
.............................................
.............................................
NDP S OINT  ............
ECT IVE ...............................
ENDPOINT & EFENDPOINT &
OGY ASSESSMEY ASSESSME
C ASSESSMSSE
RE
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  8of 873.5.1 SUMMARY OF LONG TERM FOLLOW UP DATA FROM PHASE 2B STUDY
 35
4 STUDY POPULATION ....................................................................................................... 39
4.1 INCLUSION CRITERIA ........................................................................................... 39
4.2 EXCLUSION CRITERIA .......................................................................................... 40
4.3 DISCONTINUATION/WITHDRAWAL OF STUDY SUBJECTS .......................... 41
5 STUDY TREATMENT ........................................................................................................ 43
5.1 INVESTIGATIONAL PRODUCTS .......................................................................... 435.2 BLINDING ................................................................................................................. 4 3
5.3 CELLECTRA™ 5PSP DEVICE ...................... ......................................................... 44
5.4 TREATMENT REGIMENS....................................................................................... 46
5.5 PACKAGING AND LABELING .............................................................................. 46
5.6 HANDLING AND STORAGE .................................................................................. 485.7 PREPARATION AND DISPENS  ................................................ 48
5.8 USE OF CELLECTRA™ 5PS  D ICE ..................................................... 48
5.9 INVESTIGATIONAL DRU  A  E CE ACCOUNTABILITY ...................... 49
5.9.1 INVESTIGATIONAL U  ............................................................... 495.9.2 CELLECTRA™ 5PS  DE E .................................................................... [ADDRESS_449787] ......................................................................... 49
5.10.2 CELLECTRA™ 5P  DEVICE ............................................................................ [ADDRESS_449788] DOSE 1 PHONE CALL ........................................................................ 53
WEEK 4 (±4 DAYS) ............................................................................................................ [ADDRESS_449789] DOSE 2 PHONE CALL ........................................................................ 53
WEEK 8 (±4 DAYS) ............................................................................................................ 5 4 -XQ  3URWRFRO _ 9970) _ 
$SSURYHG..
.........................
............................ ............
............................. ..........
ING ........................................
P DEVICE VICE  ................
G AND DEVICE ND DEV
PRODUCT DUCT  ..........
SP DEVICE ........ ..
ESTRUC N OFRUCTION
ATIONAL PRODATIONAL PR
TRA™ 5PSP DEA™ 5PSP DE
RES AND SS AN
VI
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  9of 87WEEK 12 (±4 DAYS) .......................................................................................................... [ADDRESS_449790] DOSE 3 PHONE CALL ........................................................................ 54
WEEK 15 (± 1 WEEK) ......................................................................................................... 54WEEK 28 ....................................................................................................................... ....... 55
WEEK 36 ....................................................................................................................... ....... 55
WEEK 40 (STUDY CONCLUSION) .................................................................................. [ADDRESS_449791] IDENTIFICATION NUMBERS ................................. 56
6.4 SAFETY EVALUATIONS ................................................................................................ 566.4.1 PHYSICAL EXAMINATION ........................................................................................ 56
6.4.2 VITAL SIGNS ............................................................................................................. .... 56
6.4.3 HEIGHT AND WEIGHT ............................................................................................ 56
6.4.4 MEDICAL HISTORY ................................................................................................. 57
6.4.5 SOCIO-BEHAVIORAL ASSESSM NT .................................................................... 57
6.4.6 LABORATORY EVALUATIO  ................................................................. 576.4.7 URINALYSIS (UA) .................................................................................................... 57
6.4.8 DEMOGRAPHICS ...................................................................................................... 57
6.4.9 URINE PREGNANCY TESTING .............................................................................. 58
6.4.10 ECG............................................................................................................................ 58
6.4.11 PARTICIPANT DIARY CAR  (PDC) SUBJECT SELF EVALUATION ............. 586.4.12 PAP SMEAR  D PV ESTING ....................................................................... 58
6.4.13 COLPOSCOP  AND CERVICAL BIOPSIES......................................................... 59
6.4.14 ECTOCERVICA  IOPSIES ................................................................................... 596.4.15 UNSCHEDULED BIOPSIES .................................................................................... 59
6.5 INJECTION AND ELECTROPORATION (EP) ........................................................... 60
6.6 MANAGEMENT OF ANXIETY AND PAIN DUE TO EP PROCEDURE ................. 606.7 ASSESSMENT OF LABORATORY ABNORMALITIES ........................................... 60
6.8 ASSESSMENT OF CLINICAL STUDY ADVERSE EVENTS ................................... 60
6.9 ASSESSMENT OF INJECTION SITE REACTIONS................................................... 606.10 PERIPHERAL BLOOD IMMUNOGENICITY ASSESSMENT ................................ 61
 62 -XQ  3URWRFRO _ 9970) _ 
$SSURYHG........
...........................
.............................................
..........................................
MENTNT...........................
ONS  ......................................
............................................
............................. ........
Y TESTINGESTING  .........
.............................................
TDIARY CARD (ARY CARD (
RS AND HPV TES AND HPV TE
OPY AND CER AND C
 IOPLB
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  10of 876.12 CONCOMITANT MEDICATIONS/TREATMENTS ................................................. 62
6.13 RESTRICTIONS .......................................................................................................... 63
7 EVALUATION OF SAFETY AND MANAGEMENT OF TOXICITY ............................. 63
7.1 SAFETY PARAMETERS .......................................................................................... 637.2 ADVERSE EVENTS (AES) ...................................................................................... 63
7.3 SERIOUS ADVERSE EVENTS (SAES) .................................................................. 647.4 UNEXPECTED ADVERSE DRUG REACTIONS AND EXPEDITED REPORTING
 65
7.5 UNANTICIPATED (SERIOUS) ADVERSE DEVICE EFFECT (UADE) .............. 66
7.6 ASSESSING SEVERITY (INTENSITY) .................................................................. 667.[ADDRESS_449792] ...................................................... 697.15 ADVERSE EXPERIENCE (AE) REPORTING ........................................................ [ADDRESS_449793] ...................................................................................................................... ...... 70
7.15.3 STUDY REPORTING PERIOD OF SERIOUS ADVERSE EVENTS ................. 70
7.16 NOTIFICATIONS OF SERIOUS ADVERSE EVENTS .......................................... 71
7.17 REPORTING OF DEVICE RELATED COMPLAINTS OR DEFICIENCIES ........ 717.18 STUDY DISCONTINUATION ................................................................................. 71
8 STATISTICAL CONSIDERATIONS.................................................................................. 72
8.1 STATISTICAL AND ANALYTICAL PLAN ........................................................... 728.2 GENERAL CONSIDERATIONS .............................................................................. 72
8.3 STATISTICAL HYPOTHESES ................................................................................ 72 -XQ  3URWRFRO _ 9970) _ 
$SSURYHG..
L MATERMATE
UES  ......................................
QUIREMENTS EMENTS  .....
SEASE PROGRES SE PRO
UDY TREATMEN TREA
ORTING PREGNA NG PREG
NG OF COLLECTOF COL
XICITY MANAGE TY MANA
NTS OF SPECIAL OF SPECIAL
XPERIENCE (AE)XPERIENCE (AE)
REPORTING PERPORTING PER
EPORTING P RT
............
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449794] OF ABBREVIATIONS ............................................................................................... 82
16 REFERENCES .................................................................................................................. ... 84
17 APPENDICES .................................................................................................................. .... 86 -XQ  3URWRFRO _ 9970) _ 
$SSURYHG........
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 13of 87Clinical Protocol Synopsis
Protocol Title : REVEAL 2, A Prospective, Randomized, Double-blind, Placebo-Controlled Phase 3 
Study of VGX-3100 Delivered Intramuscularly (IM) followed by [CONTACT_360744]™ 5PSP for the Treatment of HPV-16 and/or HPV-18 related High Grade Squamous 
Intraepi[INVESTIGATOR_190452] (HSIL)1of the Cervix
Protocol Number : HPV-303
Trial Phase : 3
Estimated Number of Trial Centers and Countries/Regions : Approximately 50 study centers in 
approximately 9 countries
Formulation : VGX-3100 delivered with CELLECTRA™ 5PSP Electroporation Device
Trial design : Prospective, Randomized, Double-blind, Placebo-Controlled
Criteria for evaluation :
Hypothesis : Among baseline biomarker-positive women, three 6 mg doses of VGX-3100 (DNA 
Plasmids encoding E6 and E7 proteins of HPV-16 and HP ) livered by [CONTACT_33813] (IM) injection followed by [CONTACT_151638] (EP) with CELLE A™ 5P  to adult women with 
histologically confirmed high-grade squamous intraepi [CONTACT_59207] e s HSIL), Cervical Intraepi[INVESTIGATOR_97596], (CIN2, CIN3) of the cervix, associated with HPV-16 and or HPV-18 will result in a higher percentage of women with histopathological regression of cervical (HSIL) lesions to no evidence of 
cervical HSIL and virologic clearance of HPV-16 and/or PV-18 compared to placebo delivered IM 
followed by [CONTACT_151678]™ 5PSP at the W k 36 visit.
2
Primary Objective : Among baseline biomarker-positive w n, determine the efficacy of VGX-[ADDRESS_449795] to combined histopat gic regression of cervical HSIL and 
virologic clearance of HPV-16 and/or HP -18.
Primary Endpoint : Proportion of baseline bio arker-positive women with no evidence of cervical 
HSIL on histology sample and no evidence of HPV-16 and/or HPV-18 in cervical samples by [CONTACT_360745] 36 .
________ ____________ ______ ____________ ______ ____________ ____________ ______ ______ ______ ____________ ______ ______ ____________ _
1Terminology based on 2012 consensus recommendation on Lower Anogenital Squamous Terminology (LAST) from 
the American Society of Colposcopy a nd Cervical Pathology (ASCCP) and the College of American Pathologists 
(CAP)
2The time frame is defined as any time starting from 14 days prior to the protocol-specified target date of Week 36. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGV-18) de18) 
CTRA™ 5PSP A™ 5PSP
thelial lesions (HSI lesions (
ith HPV PV--16 an16 an d/or Hd/
ssion of cervical (HSn of cervic
6 and/or HPV /or HPV --18 co1
t the Week 36 visit Week 32
arker -p tive womepositive w
mbined histopatholo ed histop
HPV -188.
seline arker biom -po
vidence of HPVnce of HPV -16 
visit.SS
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 15of 87Secondary Objectives Associated Secondary Endpoints
vagina and intra-anal) at Week 36 Visit
compared to baseline.
9. Among i) baseline biomarker-positive women 
and ii) all women, determine the humoral and cellular immune response of VGX-[ADDRESS_449796] dose 3 and Week 36 visit as assessed relative to baseline.9a. Levels of serum anti-HPV-16 and anti-HPV-
18 antibody concentrations at Weeks 15 and36 visits
9b. Interferon- Ȗ (/,6SRWUHVSRQVHPDJQLWXGHVDW
baseline, Weeks 15 and 36 visits
9c. Flow Cytometry response magnitudes at 
baseline and Week 15 visits.
Exploratory Objectives Associated Exploratory Endpoints -XQ  3URWRFRO _ 9970) _ 
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  16of 87Study Design
Trial Treatment : 6 mg (1 ml) VGX-3100 Intramuscular injection followed by [CONTACT_151643]™ 5PSP device given at Day 0, Week 4 and Week 12
Efficacy Assessment : The primary endpoint for the Phase 3 study (HPV-303) is based upon the results 
of the Phase 2b study (HPV-003) and the Phase 3 study (HPV-301). Given that HPV persistence is an 
important factor in the clinical progression of cervical dysplasia and also based upon the findings of the 
secondary objective of the HPV-003 study, the responder definition for the HPV-303 primary endpoint 
determination will take into consideration both histological regression of cervical HSIL and clearance of high-risk HPV-16 and HPV-18.  
Regression of cervical HSIL will be determined by [CONTACT_360746], which is considered the definitive method for diagnosis of cervical dysplasia. Tissue to be analyzed for 
evidence of histopathologic regression will be obtained at Week 36. Cervical cytology samples will be 
obtained to characterize HPV infection at screening, Day 0 (prior to dosing) and Weeks 8, 15, [ADDRESS_449797] been rendered, 
then unstained slides and/or the relevant paraffin blocks m y  ted for testing of HPV-16 and 
/or HPV-18. Vaginal, oropharyngeal, and optional intra- nal a ple  will be obtained to characterize 
HPV infection at Day 0 (prior to dosing) and at Week 36 to assess virologic response to treatment at 
sites other than the cervix.  
Immunogenicity Assessment : Humoral and cell m diate  imm  responses in response to VGX-3100 
treatment will be evaluated in blood samples taken at baseline (both Screening as well as Day 0 prior to dosing) and at Weeks 15, and 36.
 
Safety Assessment : Based upon the HP  u ts, the risk of HSIL progression to cancer or 
recurrence of HSIL is considered low and comparable to the rates observed post-LEEP/CKC [1]. The 
long-term follow-up planned for this HPV-303 stud  will include safety, cytology and HPV-16 and/or 
HPV-18 testing up to 7 months f   t dose of Study Treatment.  
A Data Safety Monitoring Bo d (D ) w l review safety data and histopathological regression 
results. The DSMB will be   sing the Sponsor if there appears to be a safety issue and 
if it appears that the proportion o   subjects with histopathologic regression in the VGX-3100 group 
is unacceptably low compared to the la ebo group. No formal interim analysis will be performed.
Trial Population : Women 18 years of age and older will be recruited in this multi-center global trial.
VGX-3100 is being developed as a non-surgical therapeutic option for the treatment of the precursor 
to cervical cancer, precancerous cervical HSIL, and the underlying pathogenic HPV-16 and/or     
HPV-18 infection. -XQ  3URWRFRO _ 9970) _ 
$SSUhe HPV PV-[ADDRESS_449798] d (DSMB ) (DSMB wilwilYHGr is lhisto
may be collec be colle
anal samples will amples w
36 to assess virologto assess vir
ell medi  immune ediated 
taken at baseline (bon at baselinYH
e charged with advie charged with adv
portion o  he subjection o  he subjec
mpared to the p d to the lac
years oye$
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 17of 87Inclusion Criteria :
Each subject must meet all of the following criteria to be enrolled in the study:
1. Women aged 18 years and above that meet the minimum age of consent per local regulations;
2. Confirmed cervical infection with HPV types 16 and/or 18 at screening by [CONTACT_360747]™ HPV test; 
3. Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis 
must be collected within [ADDRESS_449799] dose of study drug;
4. Histologic evidence of cervical HSIL as confirmed by [CONTACT_360748] (PAC)
at screening;
5. Must understand, agree and be able to comply with the requirements of the protocol; Subjects must 
be willing and able to provide voluntary consent to participate and sign a Consent Form prior to 
study related activities;
6. Must be judged by [CONTACT_343445]-specified 
procedure(s) required at Week 36;
7. Satisfactory colposcopy at screening, defined as full visualization of the squamo-columnar junction 
(Type I or II transformation zone) and complete visualization of the upper limit of aceto-white 
epi[INVESTIGATOR_360711];
8. Cervical lesion that is accessible for sampling by [CONTACT_343448] (e.g. Mini-Tischler device);
9. Cervical lesion of adequate size to ensure that a visible lesion remains after screening biopsy;
10. Must meet one of the following criteria with respect to their reproductive capacity:
a) Post-menopausal as defined by [CONTACT_343447] 12 months 
b) Surgically sterile due to absence of ovaries or due to a bilateral tubal ligation/occlusion 
performed more than 12 months prior to screening;
c) Women of Child Bearing Pot nt  ( O B ) is willing to use a contraceptive method with 
failure rate of less than 1% per yearaw n used onsistently and correctly from screening until 
Week 36. The following methods are acceptable:
• Hormonal contraception: either combined or progestin-alone including oral contraceptives, 
injectable, implants, vaginal ring, or percutaneous patches. Hormonal contraceptives must 
not be used in subjects with a history of hypercoagulability (e.g., deep vein thrombosis, 
pulmonary embolism);
• Abstinence from penile-vaginal intercourse when this is the subject’s mode of sexual 
activity;
• Intrauterine device or intrauterine system;
• Male partner steriliz n at least [ADDRESS_449800]’s entry into the study, 
and this male is the sole partner for that subject.
11. Normal screening Electrocardiogram (ECG) or screening ECG with no clinically significant 
findings, as judged by [CONTACT_093].
a Use of condoms alone or condoms with spermicide does not have a failure rate of <1% per year and is 
therefore not an acceptable form of contraception. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGsualizatioalizat
isualization of zation of
y biopsy instrument psy instrum
t a visible lesion rem sible lesion
h respect to their rep pect to their
aneous amenorrhea f s ameno
of ovaries or due ovaries 
prior to screening;r to screen
ential (WOCBP) is  (WOCBP
per year earaawh n used cwhen 
methods are acceptab ods are acce
ption: either combine : either com
nts, vagina  ring, or p aginal ring, or 
subjects w   cts with a hist
mbolism);bolism)
 from penilem penile --vaginvagin
ice or intraor 
ation
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 18of 87Exclusion Criteria :
Subjects meeting any of the following criteria will be excluded from enrollment or continuation in the 
study:
1. Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal 
(inclusive of cervical HPV-related lesions that extend into the vaginal vault), or anal intraepi[INVESTIGATOR_360712];
2. Cervical lesion(s) that cannot be fully visualized on colposcopy due to extension high into cervical 
canal at screening;
3. ECC that shows a potentially untreated carcinoma, untreated HSIL, indeterminate, or insufficient 
for diagnosis (ECC is not required to be performed as part of study screening);
4. Treatment for cervical HSIL within 4 weeks prior to screening;
5. Pregnant, breastfeeding or considering becoming pregnant through week 36 visit;
6. History of previous therapeutic HPV vaccination (licensed prophylactic HPV vaccines are allowed, 
e.g. Gardasil™, SilgardTM, Cervarix™);
7.Presence of any unresolved abnormal clinical scree  ab atory lues of Grade 1 or greater per 
Common Toxicity Criteria for Adverse Events (CTCAE) v 4.03 a  deemed clinically significant by [CONTACT_093] 60 days prior to Day 0;
8. Immunosuppression as a result of underlying illness or treatment including:
a) History of or positive serologic test for H V t een n  (performed within 60 days prior to 
Day 0);
b) Primary immunodeficiencies;
c)/RQJ WHUP XVH   GD\V RI R S QWHUDO JOXFRFRUWLFRLGV DW D GRVH RI  PJGD\ R I
prednisone equivalent; (use of inhaled, otic, and ophthalmic corticosteroids are allowed);
d) Current or anticipated use of disease modifying doses of anti-rheumatic drugs (e.g., 
azathioprine, cyclophos m , r ne, methotrexate), and biologic disease modifying drugs such as TNF- ĮLQK ibitors (e.g. infliximab, adalimumab or etanercept);
e) History of solid or n or bone marrow transplantation;
f) Any prior history  oth r  significant immunosuppressive or clinically diagnosed 
autoimmune disease that may jeopardize the safety of the subject or require therapy that would 
interfere with study assessments or endpoint evaluation, or otherwise impact the validity of 
the study results;
g) Subjects who are m l o shed (i.e. medically significant unintentional weight loss) based on 
screening labs, medical h story and physical exam per the investigator’s clinical judgment. 
9. Receipt of any non-study, non-live vaccine within 2 weeks of Dosing;
10. Receipt of any non-study, live vaccine (e.g. measles vaccine) within 4 weeks of Dosing;
11. Current or history of clinically significant, medically unstable disease which, in the judgment of the 
investigator, would jeopardize the safety of the subject, interfere with study assessments or endpoint 
evaluation, or otherwise impact the validity of the study results (e.g. chronic renal failure; angina, 
myocardial ischemia or infarction, class 3 or higher congestive heart failure, cardiomyopathy, or 
clinically significant arrhythmias);
12. Malignancy or systemic treatment for malignancy within 2 years of screening (locally treated ano-
genital malignancy and superficial skin cancers are allowed); 
13. Presence of acute or chronic bleeding or clotting disorder that would contraindicate IM injections, 
or use of blood thinners (e.g. anticoagulants or antiplatelet drugs) within 2 weeks of Day 0;
14. History of seizures unless seizure free for 5 years with the use of one or fewer antiepi[INVESTIGATOR_125796]; -XQ  3URWRFRO _ 9970) _ 
$SSURYHGed proed p
ning laboratory vaaboratory
CTCAE) v 4.03 AE) v 4.03 and 
g illness or treatment ss or treatm
for HIV at screeningHIV at s
RUDO RU SDUHQWHUDO JORU SDUHQWHU
of inhahaled, otic, andled, otic
use of disease mod of disease 
phamide, cyclosporimide, cyclos
LQKibitors (e.g. nflixbitors (e.g. i
gan or bone marrow r bone marrow 
y of other clinically y of other clinically 
isease that may jeopaase that may jeopa
 study assessments y assessments
al urishno
hi
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 19of 8715. Sustained, manually confirmed, sitting systolic blood pressure >150 mm Hg or <90 mm Hg or a 
diastolic blood pressure >95 mm Hg at Screening or Day 0;
16. Resting heart rate <50 bpm (unless attributable to athletic conditioning) or >100 bpm at screening 
or Day 0;
17. Prior major surgery within 4 weeks of Day 0;
18. Participation in an interventional study with an investigational compound or device (except HPV-
301 REVEAL 1) within 30 days of signing informed consent; participation in an observational study 
is permitted;
19. Less than two acceptable sites available for IM injection considering the deltoid and anterolateral 
quadriceps muscles;
20. Tattoos, keloids or hypertrophic scars located within 2 cm of intended treatment site;
21. Cardioverter-defibrillator or pacemaker (to prevent a life-threatening arrhythmia) that is located in 
ipsilateral deltoid injection site (unless deemed acceptable by a cardiologist);
22. Metal implants or implantable medical device within the electroporation area;
23. Active drug or alcohol use or dependence that, in the opi[INVESTIGATOR_871], would interfere 
with adherence to study requirements;
24. Prisoner or subject who is compulsorily detained (in lun r y nc erated) for treatment of either 
a psychiatric or physical (i.e. infectious disease) i
25. Active military service personnel;26. Study-related staff or family member of study-r lated staff;
27. Any illness or condition that in the opi[INVESTIGATOR_1101] h  investigator may affect the safety of the subject 
or the evaluation of any study endpoint. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGele
opi[INVESTIGATOR_360713];ss;
dy-ree  ; lated staff;
on of the investigato the invesR
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 20of 87Schedule of Events
Table 1: Schedule of Events
Tests
Screening*
(-10 weeks to -1 Day
from date of biopsy)WeeksDay [ADDRESS_449801] Day 0
Phone Call
4 (± 4 days)
8-[ADDRESS_449802] Wk 4
Phone Call
8 (± 4 days)
12 (± 4 days)
8-[ADDRESS_449803] Wk 12
Phone Call
15 (± 1 week)
28 (± 1 week)
36 (± 1 week)
40 (± 2 weeks)
Informed consent X
Medical History X
Demographics X
Socio-behavioralaX XX
Inclusion / Exclusion X X
Randomization X
Physical exam/assessmentbXX X X X X X X
Vital signs XcXX X XXX
Screening safetydX
Pregnancy TesteXX X X X X X
HIV Antibody Testing Xq
Blood immunologic samplesfXqXXgX
Cervical digene brushesi, jXqXX X
ThinPrep™ h, iXqXX X X
ColposcopykXl, qXX X X X
Ectocervical biopsymXq
Surgical excisionmXn
OP rinse, vaginal swabs, intra-
anal swabso XX
Inject VGX-3100/Placebo X X X
Post treatment assessment X X X X X X XpX
AE/SAE assessment X X X X X X X X X X X X
Distribute Participant Diary Card
(PDC)XX X
Review PDC X X X Xp
aSocio-behavioral assessments, e.g. self-reported smoking and alcohol history; -XQ  3URWRFRO _ 9970) _ 
$SSURYHGGGGGGGGGGGGHGGHGHGHGGGHGGYYYHYHYHYYHYYYHYHYHRYYHXRYRYRYYYRYY
X XRRRUURUUURURRSUURXXSUSUSUUSSSUU
XqSSSSSSSSSSSXqXSSSSSSSS$SSS XXqqXX$S$S$SSS$$SS
XXqqX$$$S$S$S$$$SXll, q, q$$$$
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 21of 87bComplete physical examination (PE) mandatory at screening and study discharge (Week 40), otherwise 
targeted physical assessment as determined by [CONTACT_360749] a complete PE;
cScreening vital signs must include a measured height and weight. Height and weight will be collected on 
Day 0, Weeks 4 and 12;
dScreening safety procedures includes 12-Lead ECG, complete blood count (CBC), serum electrolytes, blood urea nitrogen (BUN), serum creatinine (Cr), serum Albumin, serum glucose, serum ALT, serum 
CPK and urinalysis performed within 60 days prior to  Day 0;
eFor WOCBP, a negative spot urine pregnancy test is required at screening and prior to each study 
treatment, colposcopy and surgical excision;
iRequest that the subject abstain from sexual activity and refrain from use of douching or vaginal lubricants/medication for a period of 24 hours prio  t  cervical specimen collection;
jCollected prior to the ThinPrep™ sample ;
kAcetic acid should be applied to lesions b f  co pi  e aminations for the Screening and Week 36 
visits; 
lScreening colposcopy is optional if ad  c o y as performed upon collection of initial biopsy;
mScreening biopsy of the lesion should be collected  paraffin-embedded cervical tissue, fresh cervical tissue, or H&E slides. In the absence of par in-embedded or fresh tissue, unstained slides will be 
required in addition to H&E slide  Tissue to be analyzed for evidence of histopathologic regression will 
be obtained at Week 36 by [CONTACT_148995] (e.g. LEEP, LLETZ, CKC);
nSlides from biopsy and/or excised tissue must be reviewed by [CONTACT_360750]/or Week 36 specimen(s) (paraffin blocks or unstained slides) may be used for assessment 
of  as well as HPV testing;
oPlease refer to the Laboratory nual for specific information regarding biological sample collection;
pActivities at [ADDRESS_449804]-Dose 3 phone call may be done at Week 15 if timing overlaps;
qResults and activities performed as part of the screening process in the HPV-301 trial can be used as qualifying historical information to satisfy screening activities for HPV-303 provided that they were 
assessed within the required timeframes for HPV-303 screening. -XQ  3URWRFRO _ 9970) _ 
$SSURYactivity and efrain ty and ref
prior to cervical sper to cerv
efore colposcopic excolposco
dequate ecolposcopy wcolpos
ould be collected as be collected
bsence of paraffin e of para -
ides. Tissue to be anTissue to be a
excision (e.g. LEEP, on (e.g. LEEP,
r excised tissue mustexcised tissue mu
36 specimen(s) (parspecimen(s) (par
as well ass well as HPV
ory Manual fMan
Dose 3D
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  22of 871 INTRODUCTION
1.1 BACKGROUND AND SCIENTIFIC RATIONALE
Infection with human papi[INVESTIGATOR_28597] (HPV) can lead to malignant neoplasia, localized primarily in the ano-
genital area and aero-digestive tract, in both men and women. HPV types tropic to mucosal tissues are 
classified into high-risk (HR), based on their potential to cause cancer, and low-risk (LR) (causing generally 
benign lesions). HPV-[ADDRESS_449805] HPV-caused cancers [ 2]. In the US alone, approximately 14 million new genital HPV 
infections occur annually, and approximately half of these infections are with a high-risk HPV type [ 3, 4].  
Up to 13,000 women in the US alone are diagnosed with cervical cancer each year, with an estimated 4,120 
deaths annually in year 2017 [ 5]. HPV-[ADDRESS_449806] common high-risk genotype and combined with HPV-
18 these two genotypes are estimated to cause about 70% of all cervical cancers [6],[7] .
Incident infection by [CONTACT_360751] (grade 1 cervical intraepi[INVESTIGATOR_360714] i ) en the female cervix is infected with 
HPV. Most cases of genital HPV infection clear spontan ly  bu  r istent infection with one or more 
oncogenic (high-risk) HPV genotypes can lead to the development of precancerous, histologic high grade 
squamous intraepi[INVESTIGATOR_314564], HSIL which is inclusive of grade 2 and 3 cervical 
intraepi[INVESTIGATOR_28601] (CIN2/3) [8]. Over time, typi[INVESTIGATOR_343339], cervical HSIL can progress to invasive 
cancer of the cervix [9 , 10]. The basis for these changes are attributed to the viral proteins E6 and E7.  
Infected cells produce E6 and E7 constitutively i  i s  the degradation of cell cycle regulation 
proteins p53 and pRb, respectively, resulting in unrest c  ce  growth and neoplasia.
1.2 BACKGROUND INFORMATION
While the currently available prophylac ic V vaccines (Cervarix™, Gardasil™, and Gardasil™-9) are highly effective in preventing persistent infection and the subsequent development of high-grade CIN 
caused by [CONTACT_33968]-16, HPV-[ADDRESS_449807] 
upon existing HPV infection or ex s  P - e ted intraepi[INVESTIGATOR_28601] [1 1]. This means that the 
large number of women who already h ve high grade cervical dysplasia, either because they were too old to have received the prophylactic vaccine or they did not respond to vaccination, must currently rely upon 
surgery and the chance of spontaneous regression to treat their condition and avoid progression to cancer.  
Furthermore, the number of US  teenagers who complete the prophylactic vaccination series 
remains low; 39.7% of US girls ages 13-17 completed their prophylactic HPV immunization series in 2014, 
which leaves a potentially vulnerable, under-protected population [ 12]. The current approaches to the 
management of cervical HSIL typi[INVESTIGATOR_1435] s urgery (i.e. LEEP/LEETZ, laser ablation, or conization); 
however, surgical excision does not necessarily address the underlying HPV-infection, and can adversely 
impact the reproductive health of women of childbearing age. Therefore, VGX-[ADDRESS_449808]
VGX-3100 contains plasmids that encode HPV-16 E6/E7 and HPV-18 E6/E7 antigens. The plasmids were 
designed and constructed using Inovio’s proprietary SynCon™ (synthetic consensus) technology. This  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGplicaplic
pl  hasia) w
eously  but persi y, but per
evelopment of precaopment of p
SIL which is inclus which is in
typi[INVESTIGATOR_343339], cerv ally years, 
e changes are attribu nges are a
ly which increases t ich incre
g in u st nres ricted cell rictttt
ION
lactic HPV vaccinesc HPV vacc
sistent infection andnt infection
d other HPV types, her HPV typ
or existing HPV isting HPV -relarela
o already have high o already have high 
hylactic vaccine or thactic vaccine or th
f spontaneous regre ntaneous regre
of USUS-eligible
ages 13ge
abl
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  23of 87process involves synthetically deriving consensus genes across multiple strains and optimizing DNA inserts 
at the genetic level to allow high expression in human cells. The initial formulation of VGX-3100 was water for injection with 1% w/w poly-L-glutamate (WFI/LGS) that required frozen storage and was administered
by [CONTACT_360752]™ 2000 device. The frozen formulation has been administered to more than 250 
subjects in Phase 1 and 2 clinical trials. Proof of concept was demonstrated in the prospective, randomized, 
double blind, placebo-controlled HPV-003 study of VGX-3100 (frozen formulation) followed by [CONTACT_360753]-grade cervical dysplasia, cervical HSIL associated with HPV-16 and/or HPV-18. HPV-
003 dosed 167 subjects with high grade cervical dysplasia from seven countries and one [LOCATION_002] 
Territory (Australia, Canada, Estonia, Republic of Georgia, India, South Africa, [LOCATION_002] and Puerto 
Rico). Subjects were randomized in a 3:1 ratio to the treatment arm (VGX-3100, frozen formulation) or the 
placebo arm, respectively. All subjects received treatment on Day 0, Week 4 and Week 12. All subjects 
repeated cervical biopsy or LEEP of the cervix at Week 36 to assess efficacy defined as regression of high 
grade CIN by [CONTACT_27183]. The primary endpoint was histopathologic regression of cervical lesions (CIN2 or 
CIN3) to CIN1 or less at the Week 36 visit. A secondary endpoint was clearance of HPV-16/18 in combination with histopathologic regression of cervical lesions to C 1 or less. The proportions of subjects 
who met the primary and secondary endpoints were significantly higher in the VGX-3100 group vs. Placebo 
in both per protocol and modified intent to treat analyses. T-cell activity was detected in VGX-3100 
recipi[INVESTIGATOR_316666]. VGX-310  demonstrated an acceptable safety profile when 
administered intramuscularly followed by [CONTACT_360754] 3 program, a buffered refrigerated (2– q C storage) formulation of VGX-3100 
was developed using a saline sodium citr  S   The refrigerated formulation requires 
administration using the next generation device, the CELLECTRA™ 5PSP. This refrigerated formulation 
of VGX-[ADDRESS_449809]   a P se 1 clinical trial, HPV-101. Roughly half the 
healthy volunteers in the HPV-101 study, received r e 6 mg IM doses of VGX-3100 (refrigeratedformulation) followed by [CONTACT_151658]. Base   n l sis of the data, the refrigerated formulation was 
determined to be non-inferior to the frozen r n based upon a 2-fold rise in overall Spot Forming Units (SPU) to the antigens encoded   s ds per 10
6 peripheral blood mononuclear cells (PBMC) 
as measured from baseline to Week 14 using the interferon- Ȗ (/,6SRW assay. 
1.3.2 CELLECTRA™ DEVICE DEVELOPMENT 
CELLECTRA™ 2000 & P a e l c roporation (EP) devices. EP is a physical method of tissue 
transfection whereby [CONTACT_360755] a on  hort, controlled electrical pulses creates a localized electrical field 
at the injection site which increas  l membrane permeability and improves the transfection of DNA and 
subsequent immunogenicity [1 3, 14] . EP is believed to increase the uptake and processing of plasmid DNA, 
thereby [CONTACT_360756] 10 to 100-fold [1 5, 16 ]. This 
technology has been used for more than three decades by [CONTACT_360757], as shown by [CONTACT_343459] a range of molecules, 
tissue types, disease indications, and across species [1 3]. The CELLECTRA™ device developed by [CONTACT_360758]-based DNA, in both prophylactic and therapeutic 
settings. Following successful proof-of-concept studies in animals, Inovio has optimized both pulse pattern and voltage to increase transfection efficiency and has demonstrated that the device helps to elicit favorable 
immunogenicity in several species (e.g., mice, pi[INVESTIGATOR_14107], and rhesus macaques) [1 4, 15 ].  
In preparation for the Phase 3 program, a next generation device, CELLECTRA™ 5PSP, was created to 
address ergonomic functionality and automate the delivery of VGX-3100 and EP. The technology  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGen
n  I Ns to C
antly higher iny higher in
yses. T- T-cell activitcell act
0demonstrated an monstrated
rationn.
ed refrigerated frigerate (2–8q
ate (SSC) solution.(SSC) solut
vice, the CELLECT the CEL
17subjubjects in a Phascts in a 
tudy,receiv recei ed three
ed upon an analysis on an ana
hefrozenzenformulatioform
oded   m d by [CONTACT_360759] 14 using the in 14 using the in
CTRATRA ™ ™ DEVICDEVIC EE
5PSP areSP elect
erati n of shion
escel
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  24of 87differences between the CELLECTRA™ 2000 and CELLECTRA™ 5PSP design do not affect the intended 
mechanism of EP on the activity of VGX-[ADDRESS_449810] the indications for use, operating principle, energy type, or sterilization 
specifications. The CELLECTRA™ 5PSP has been approved for investigational use in the US with VGX-3100 and is being used in a Phase 3 clinical study HPV-301, titled “A Prospective, Randomized, Double-
blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly (IM) followed by [CONTACT_343425]™ 5PSP for the Treatment of HPV-16 and/or HPV-18 related High 
Grade Squamous Intraepi[INVESTIGATOR_190452] (HSIL) of the Cervix”.
Together, VGX-3100 and the CELLECTRA™ device represent an integrated product designed as a non-
surgical treatment for HPV-16/18-related cervical HSIL (CIN2, CIN3) via an immune response directed 
against HPV-16/18. Therefore, the refrigerated formulation of VGX-3100 and the CELLECTRA™ 5PSP device were chosen to progress into Phase [ADDRESS_449811] been completed prior to the start of Phase 
3. The intent is to support that the dimensional changes, change to the ergonomics of the patient user 
interface and injection method result in the CELLECTRA™ 5PSP de ice design meeting its safety and 
performance specifications. The mechanical process f ad nistration has changed from manual to 
automatic, but the overall administration of VGX-3100 foll d by [CONTACT_360760]™ 2000. Inovio’s device experienc  de ns a e  hat delivery of its proprietary electroporation pulses into muscle immediately fol i g injection f DNA plasmids (including VGX-
3100) is well-tolerated in humans and no signific  f t  ssues have been identified [ 1], [14], [16]. For 
further information concerning the 5PSP de e plea  r to the User Manual and the Investigator’s 
Brochure.
1.3.[ADDRESS_449812] higher response rates and magn des of IFN- Ȗ (/,6SRW UHVSRQVHV FRPSDUHGWR WKHORZ 
mg) and mid-dose (2 mg) cohorts ( Table 2 ) without significant safety issues [ 14]. 
This dose-trend was consistent w h or expectation, a feature of the finding that suggests it is a true effect rather than random variation. Adverse events from previous human studies with VGX-[ADDRESS_449813] that the 6 mg dose was efficacious with an acceptable safety profile, therefore the 6 mg 
dose will also be evaluated in this Phase 3 trial [ 1]. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGhange tange
A™ 5PSP dev 5PSP dev
of administration ministratio
0 followed by [CONTACT_360761] e
nce demonstrates t demonstr
following injection o ing injecti
icant y ssues hasafety i
vice please refer to please refe
A has been selected f s been selec
ated fn s  oormulatio
y and immunogenic d immunogeni
V-001 trial, the 6 mgtrial, the 6 mg
nse rates and magnituse rates and magn
) cohorts (horts ( ble 2 Table )) w w
nt with prior with 
dverse dv
b
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  25of 87Table 2:  Percent of Protocol HPV-001 Subjects Responding and Average SFU/106PBMC 
in Responders for each Antigen by [CONTACT_360762]- Ȗ (/,6SRW
Cohort Low Mid High
Antigen %Response AVG %Response AVG %Response AVG
HPV-16E6 33% 107 50% 243 50% 1341
HPV-16E7 17% 198 50% 104 67% 143
HPV-18E6 50% 359 50% 338 83% 664
HPV-18E7 33% 159 17% 179 50% 834
Any 67% 221 67% 210 83% 556
1.4 POTENTIAL RISKS AND BENEFIT
1.4.1 POTENTIAL RISKS
Risks associated with VGX-3100 for the treatment of i rade ce vical dysplasia are injection site 
reactions related to the IM injection and/or electroporati .  Based on the Phase 1 and 2 clinical experience, 
the injection site reactions associated with the IM injection and electroporation are generally mild (e.g. erythema) and limited to a few days in duration at most.   
A potential risk is the delay of surgical intervent on of the high-grade cervical dysplasia and possible missed 
diagnosis of an occult early invasive cerv  c r  the VGX-3100 non-responders or placebo 
recipi[INVESTIGATOR_840], who do not spontaneously regress. Alth  rofessional guidelines typi[INVESTIGATOR_360715]  w th v  HSIL, scientific data indicates that the rate of 
progression from pre-invasive to inva   a  is slow, typi[INVESTIGATOR_360716] 
[8]. The risk of a missed diagnosis o   o c  sive cervical cancer exists for all current treatment 
modalities including surgical and ablative therapi[INVESTIGATOR_014]. Furthermore, approximately 17-18% of patients with 
high grade CIN will experience rence of dysplasia following surgical intervention [ 8], which illustrates 
that current standard of care for cervical dysplasia requires improvement. To mitigate these potential risksthe study design includes numerous s feguards to detect disease progression or the presence of an 
undiagnosed occult earl  invas  c l cancer. These include careful selection of immunocompetent patients, thorough screening and baseline evaluation, frequent cervical colposcopy, cytology and high-risk 
HPV testing throughout the tr  e t gators will be comprised of experienced gynecologists, who will have the discretion to obtain biopsies at any point if disease progression is suspected. 
A Data Safety Monitoring Board (DSMB) will also advise the Sponsor if it appears that the frequency of 
regression in the VGX-3100 group is unacceptably low compared to the placebo group.  These measures 
should minimize the risk of progression of the cervical HSIL and the risk of harboring an undiagnosed occult early invasive cervical cancer. Secondary to the potential risk of progression to cancer during the 
course of the trial described above, all subjects with the suggestion of residual disease will undergo 
excisional therapy (e.g. CKC, LEEP, LLETZ) at Week 36 as part of the efficacy assessment. In the HPV-
003 study, the percentage of subjects with micro-invasive cancer found in larger surgical excision samples 
in subjects who had no evidence of invasive cancer by [CONTACT_360763] 1.8%, (2/114 with specimens), which is consistent with that reported under standard of care settings [ 17]; never the less, all subjects will 
undergo excision at Week 36 to ensure no evidence of occult progression.  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGhigh-grade cervgrade cer
on.  Based on theBased on the Ph
njection and electrop on and ele
most.    
ion of the high f the high -grade
ical cancer for the cancer
egress. Although pss. Althou
s wi hth cervi al HSIcervical 
sive cervical disease cervical di
f an occult earlyoccult early inva
ablative therapi[INVESTIGATOR_014]. ve therap F
recurrence of dysplas rence of dyspla
for cervical dysplasia vical dysplasia
numerous safeguarnumerous safegu
y invasive cervical c asive cervical c
ng and baseline end baseli
rial. InvestiIn
sies a
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  26of 87For further information concerning the risks associated with VGX-3100 and the CELLECTRA™ 5PSP 
device please refer to the User Manual and the Investigator’s Brochure.
1.4.2 POTENTIAL BENEFITS
Subjects that participate in the study may potentially see benefit from the investigational treatment if it 
proves efficacious. The close follow-up required by [CONTACT_360764](s). Overall, the study results will provide new information that may benefit 
other subjects in the future.  
1.5 RISKS FOR CURRENT TREATMENT
Currently, treatment of women with cervical HSIL usually consists of either surgical removal of the affected 
tissue by [CONTACT_360765], LEEP, ablative therapy via laser, or cryotherapy. All treatments for cervical HSIL are 
associated with a variety of short and long term general and reproductive health risks as listed in Table 3 . -XQ  3URWRFRO _ 9970) _ 
$SSURYHG
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 27of 87Table 3: Risks Associated with Surgical Treatments for Cervical HSIL
Surgical Treatments for 
Cervical HSIL Risks
CKC
LEEP
Ablative therapy (Laser or 
Cryotherapy)Pain
Exposure to anesthesia
Heavy bleeding
Infection
Menstruation problems
Cervical stenosis (can lead to a lteration of squamo-columnar junction)
Shortening of the cervix
Decreased fertility/difficulty getting pregnant
Cervical incompetence
Pre-term birth and elated low birth weight
Incomplete treatment f cervical dysplasia
Inadequate treatment of an occult early invasive cancer
Adapted from FAQs Loop Electrosurgical Excision Procedure (LEEP) American College of Obstetricians and 
Gynecologists (2014) [12] .
More importantly, none of the currently avail ble gi a  t tments for cervical HSIL eradicate the 
underlying cause of the high-grade cervical dysplasia, persistent infection with one or more of the high-risk 
HPV types, and therefore, leaves patients t r sk for recur  cervical HSIL as well as high grade dysplasia of the vulva and vagina due to the potentially broader infection of the genitourinary area.
[ADDRESS_449814] to combined histopathologic regression of cervical HSIL and virologic clearance of HPV-16 
and/or HPV-18.
2.1 HYPOTHESIS
Among baseline biomarker-positi e women, three 6 mg doses of VGX-3100 (DNA Plasmids encoding E6 
and E7 proteins of HPV-16 and HPV-18) delivered IM followed by [CONTACT_151678]™ 5PSP to adult women with histologically confirmed HSIL of the cervix, associated with HPV-16 and/or HPV-18 will 
result in a higher percentage of women with histopathologic regression of cervical HSIL lesions to no evidence of cervical HSIL and virologic clearance of HPV-16/18 compared to placebo delivered IM 
followed by [CONTACT_151678]™ 5PSP at the Week [ADDRESS_449815] to histologic regression of cervical 
HSIL and clearance of the underlying HPV 16/18 infection. HPV-303 is a prospective, randomized, double-blind, placebo-controlled study to determine the efficacy, safety, and tolerability of VGX-3100 
administered by [CONTACT_360766]™ 5PSP device in adult  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGvical iica
rth and elatend elaGete trea m   cerv tment of G treatment of an occultment of an ocHGHon Procedure (LEEP) cedure (LE
vaila  ical trea ble surg
dysplasia, persistentplasia, per
 at ri  o  rrent sk for recur
entially broader infec ly broader
PURPOSE POSE 
sitive women,e women ddetereter
stopath ologiologi c regressc regress
tive wov
V
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 28of 87women with histologically confirmed cervical HSIL (CIN2, CIN3) associated with HPV-16/18. A placebo-
controlled study is selected for this trial because it provides scientific rigor to distinguish an effective 
treatment, particularly in cervical HSIL for which spontaneous regression does occur.
To be eligible for the study, subjects at least [ADDRESS_449816] cervical biopsy/biopsies of the cervical lesion(s) at the time of Screening. Slides of the 
biopsy will be sent to the PAC in a blinded manner to establish the presence of cervical HSIL within screening. In order to be eligible for randomization, the PAC must assign the histologic diagnosis of cervical 
HSIL. Subjects must also have a cervical specimen test positive for HPV-16/18 by [CONTACT_360747]™ HPV test to be eligible for participation in the study.
A sample of approximately 198 subjects will be randomized to receive either 6 mg (in 1 ml) VGX-3100 or 
placebo, each IM followed by [CONTACT_151658], in a 2:1 ratio. This sample size provides >90% power to declare VGX-
3100 superior to placebo among biomarker-positive women, assuming, based upon HPV-301 study results, 
that the true proportion of subjects whose lesion(s) regress a  hose HPV-16/18 clear is 66% and 15% 
for VGX-3100 and placebo, respectively, and that the proportion of biomarker-positive women is 33%.  
Biomarker positivity in this context is defined as being predicted to exhibit lesion regression concomitant with HPV-16/18 clearance after interrogation of a pre-de i d NA (miRNA) signature [CONTACT_360827]  X-3100 or placebo. Those subjects who are not 
predicted to exhibit lesion regression and HPV-16/18 clearanc  based on this signature [CONTACT_360828]-3100 or placebo are considered biomarker-ne
Subjects will be randomized in a stratified manner according to (a) the CIN severity observed in the biopsy 
specimens at screening (i H&,1YV&,1 , D HJRU\ 25 vs. > 25 kg/m
2) on Day 0, and (c) age 
category (< \HDUVYV 25 years) on Day 0.  e 2 disease is not over-represented in the study, 
the percentage of subjects enrolled wi  IN2 will not exceed 50% of the total enrolled. Each country will 
receive a group of sequential allocation numbers.
3.[ADDRESS_449817] to combined histop thologic regression of cervical HSIL and virologic clearance of HPV-16 
and/or HPV-18.
3.1.1 PRIMARY ENDPOINT & EFFICACY ASSESSMENT
The primary endpoint for HPV-303 is based upon the results of HPV-003 and HPV-301 and is identical to 
the primary endpoint of the HPV-301 study, but for a biomarker-positive population. Given that HPV persistence is an important factor in the clinical progression of dysplasia and also based upon the findings 
of the secondary objective of the HPV-003 study, the responder definition for the HPV-303 primary 
endpoint determination will take into consideration both histological regression of cervical HSIL and clearance of high-risk HPV-16/18. The composite endpoint of histologic regression and virologic clearance will be primary in the HPV-303 study, and histologic regression will be a secondary endpoint.
3.1.2
HISTOLOGY ASSESSMENT
Regression of cervical HSIL will be determined by [CONTACT_360746], which is considered the definitive method for diagnosis of cervical dysplasia. Tissue to be analyzed for evidence of histopathologic regression will be obtained at Week 36by [CONTACT_148995] (e.g., LEEP, LLETZ, CKC).  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGnd whnd w
portion of brtion of
redicted to exhibi ed to exh
defi  NAned microR
of VGX X--3100 or pla3100
18 clearance based o earance bas
neg iative.
anner according to ( r accord
 , D HJRU\E%0,FDW
Day 0 .To ensu e To ensure CIN
th CIN2 will not excIN2 will no
tionnumbers. numbers.
VE
positp ive women , e women det
histopathologic regrstopathologic regr
ENDPOND
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  29of 873.1.3 VIROLOGIC ASSESSMENT
Cervical cytology samples will be obtained to characterize HPV infection at screening, Day 0 (prior to 
dosing) and Weeks 8, 15, [ADDRESS_449818] been rendered, then unstained slides and/or the relevant paraffin blocks may 
be collected for testing of HPV-16/18. Vaginal, intra-anal, and oropharyngeal samples will be obtained to 
characterize HPV infection at Day 0 (prior to dosing) and at Week 36 to assess virologic response to 
treatment at sites other than the cervix. 
3.1.4
DEFINITION OF RESPONDER AND NON-RESPONDER
Responder and non-responder definitions ( Table 4 ) for the primary endpoint takes into account both 
histopathologic regression of cervical HSIL and virologic (HPV-16 and/or HPV-18) clearance from 
cervical samples since HPV persistence is an important factor in the clinical progression of HSIL. The 
responder definition also excludes subjects who undergo excision or whose cervix is biopsied at any time 
after their initial dose and before the Week [ADDRESS_449819] caused by [CONTACT_360767]-16/18 by [CONTACT_360768].   
To qualify as a responder for the primary endpoint, t  t  hav : 
1) An acceptable histology specimen at the Week time frame, w h is interpretable by [CONTACT_360769] 
2) An acceptable HPV ThinPrep™ sample at the Wee  [ADDRESS_449820] with: 
- Histologic evidence of cervica  HSIL, or 
- Evidence of HPV-16 or HPV-18, or  
- An excision or biopsy sample obtained between initial dose and the Week 36 evaluation, or  
- No Week 36 visit sample/result -XQ  3URWRFRO _ 9970) _ 
$SSURYHGsue coue c
he treatmentreatme
biopsies.  s.
he sub ect m  have ject must 
36tie fram e me frame , hicw
ttheW  6 Week 3 time f
th: 
cervical HSIL cal HSIL
6 or HPV-18  HPV-18  
ot hav e had an unsche had an unsch
Week 36 evaluationWeek 36 evaluatio
responder nder any subjny subj
of rvicalcer
P
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 30of 87Table 4: Definition of Composite Regression and Clearance Endpoint Responder and Non-
Responder
Responder Non-Responder
Subject with no histologi c evidence of cervical 
HSILaat Week 36 evaluation and no evidence of 
HPV-16 and/or HPV-[ADDRESS_449821] 
recent HPV clearance result prior to tissue removal, which includes results from the same date, within the timeframe determines 
the HPV clearance endpoint.
c Excludes ECC-only samples.
3.2 SECONDARY OBJECTIVE S AND ENDPOINTS
Secondary Objectives Associated Secondary Endpoints
1. Among i) baseline biomarker-positive w men 
and ii) all women, evaluate the safety and 
tolerability of VGX-3100 delivered IM 
followed by [CONTACT_151678]™5PSP.1a. ence and severity of local and systemic 
events for 7 and 28 days following each 
investigational treatment and for the duration 
of the study (i.e., 40 weeks).
1b. Incidence and severity of all adverse events 
including Serious adverse events (SAEs) 
(e.g., Serious unexpected serious adverse 
reaction (S[LOCATION_003]R), Unexpected adverse 
device effect (UADE) and other unexpected AEs) for the duration of the study (through 
Week 40 visit).
2. Among all women, determi  t e efficacy of 
VGX-[ADDRESS_449822] to combined histopathologic 
regression of cervical HSIL and virologic 
clearance of HPV-16 and/or HPV-18.2. Proportion of all women with no evidence of 
cervical HSIL on histology sample and no 
evidence of HPV-16 and/or HPV-18 in 
cervical samples by [CONTACT_360770] 36 visit.
3. Among i) baseline biomarker-positive women 
and ii) all women, determine VGX-3100 efficacy compared to placebo as measured by 
[CONTACT_360771].3. Proportion of women with no evidence of   
cervical HSIL on histology sample at Week 
36 visit.
4. Among i) baseline biomarker-positive women 
and ii) all women, determine VGX-3100 efficacy compared to placebo as measured by 4. Proportion of women with no evidence of 
HPV-16 and/or HPV-18 in cervical samples 
by [CONTACT_360745] 36 
visit. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGor surgir sur
oval sample dal sample
ts from the same m the same
NDPOINTSPOINT
AssRYRYRYRY
positive w men ive women
the safety and safety and 
delivered IMvered IM
ELLECTRA CTRA™5PSP5PSP1a.1aIncid
ev
iRYRYRYURY
ne the$
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 31of 87Secondary Objectives Associated Secondary Endpoints
virologic clearance of HPV-16 and/or HPV-
18.
5. Among i) baseline biomarker-positive women 
and ii) all women, determine VGX-3100 
efficacy compared to placebo as measured by [CONTACT_360772].5. Proportion of women  with no evidence of 
Low grade squamous intraepi[INVESTIGATOR_112716] 
(LSIL) or HSIL (i.e., no evidence of CIN1, CIN2 or CIN3) on histology sample at Week 
36 visit.
6. Among i) baseline biomarker-positive women 
and ii) all women, determine VGX-3100 
efficacy compared to placebo as measured by 
[CONTACT_360773]-16 and/or HPV-18.6. Proportion of women with no evidence of 
LSIL or HSIL (i.e., no evidence of CIN1, 
CIN2 or CIN3) on histology sample and no 
evidence of HPV-16 and/or HPV-18 by [CONTACT_360774] f c HPV testing at Week 36 visit.
7. Among i) baseline biomarker-positive women 
and ii) all women, determine VGX-3100 efficacy compared to placebo as measured by 
[CONTACT_360775]-progression.7. Proportion of w men with no progression of 
cervical HSIL to cervical carcinoma from 
baseline on histology sample at Week 36 
visit.
8. Among i) baseline biomarker-positive w en 
and ii) all women, describe the clearan  f HPV-16 and/or HPV-[ADDRESS_449823] cleared 
HPV-16 and/or HPV-18 on specimens from 
non-cervical anatomic locations (oropharynx, vagina and intra-anal) at Week 36 Visit
compared to baseline.
9. Among i) baseline biomarker-positive women 
and ii) all women, determine the humoral and cellular immune respon  f V X-[ADDRESS_449824] dose 3 and 
Week 36 visit as assessed relativ  to baseline. 9a. Levels of serum anti-HPV-16 and anti-HPV-
18 antibody concentrations at Weeks 15 and 
36 visits
9b. Interferon- Ȗ (/,6SRWUHVSRQVHPDJQLWXGHVDW
baseline, Weeks 15 and 36 visits
9c. Flow Cytometry response magnitudes at 
baseline and Week 15 visits.
3.2.1 HISTOLOGY ASSESSMENT
Regression of cervical HSIL will be determined by [CONTACT_360746], which 
is considered the definitive method for diagnosis of cervical dysplasia, for all subjects. Tissue to be analyzed for evidence of histopathologic regression will be obtained at Week 36 by [CONTACT_148995] (e.g., LEEP, LLETZ, 
CKC).
3.2.2
VIROLOGIC ASSESSMENT
Cervical cytology samples will be obtained to characterize HPV infection at screening, Day 0 (prior to 
dosing) and Weeks 8, 15, [ADDRESS_449825] been rendered, then unstained slides and/or the relevant paraffin blocks may be collected for testing of HPV-16/18. Vaginal, intra-anal, and oropharyngeal samples will be obtained to  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGence
ef c  Pcific H
Proportion of ortion of wo
cervical HSIL tocervical HS
baselin  on hibaseline
visit.visit.GYomen 
ce of 
om non on-8.8P oportioPo
HPV-[ADDRESS_449826] dose 3 an
sessed relativ  to ba d relativ  to baSUUU9aU
$U
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 32of 87characterize HPV infection at Day 0 (prior to dosing) and at Week 36 to assess virologic response to 
treatment at sites other than the cervix.
3.2.3 DEFINITION OF RESPONDER AND NON-RESPONDER
Table 5: Definition of Secondary Regression Endpoint Responder and Non-Responder
Responder Non-Responder
Subject with no histologi c evidence of cervical 
HSILaat Week [ADDRESS_449827] tissue r al s  determines the histology endpoint.
cExcludes ECC-only samples
Table 6: Definition of Secondary Complete Re ression Endpoint Responder and Non-
Responder
Responder Non-Responder
Subject with no histologi c evidence of cervical 
HSIL squamous atypia, or LSIL at Week [ADDRESS_449828] tissue removal sample determines the histology endpoint.
b Excludes ECC-only samples.
Table 7: Definition of Secondary Non-progression Endpoint Responder and Non-Responder
Responder Non-Responder
Subject with no histologic evidence of a worsening 
of cervical condition at Week [ADDRESS_449829] tissue removal sample determines the histology endpoint.
b Excludes ECC-only samples -XQ  3URWRFRO _ 9970) _ 
$SSURYHGGia, or LSa, or L
psy or surgical surgic
removal sample dete l sample de
Reg es  ndporession EYal
visita
amplebwa wa  
to We k [ADDRESS_449830] underg
t date of Week 36. The ft date of Week 36. T
ondary Ndar
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 33of 87Table 8: Definition of Secondary Composite Complete Regression and Clearance Endpoint 
Responder and Non-Responder
Responder Non-Responder
Subject with no histologi c evidence of cervical 
HSIL, squamous atypia, or LSILaat Week 36 visit
and no evidence of HPV-16 and/or HPV-[ADDRESS_449831] recent HPV clearance result prior to tissue removal, wh ich includes results f m the same date, within the timeframe 
determines the HPV clearance endpoint.
c Excludes ECC-only samples
Table 9: Definition of Secondary Clearance Endpoint Responder and Non-Responder
Responder Non-Responder
Subject with no histol ogic evidence of HPV-16 
and/or HPV-[ADDRESS_449832] recent 
HPV clearance result prior to tissue re al wit in e timef a e determines the HPV clearance endpoint.
bExcludes ECC-only samples
cThis applies only to the cervical clearance endpoint.
3.3EXPLORATORY OBJECTIV  AND ENDPOINTS -XQ  3URWRFRO _ 9970) _ 
SSURYHGal sampl sa
esults from ults from
Endpoint Responpoint ReYH
ebwas s 
Week [ADDRESS_449833] tissue rem
moval within the timefram within the timefram
clearance endpoint.earance endpoint.
OBJ ESJECTIV
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449834] an even 
wider margin of safety and an opportunity to explore predictors of efficacy. Safety monitoring and visit 
frequency has been designed to take into account the potential risk of delay in the usual treatment of the 
high-grade cervical dysplasia and also the potential for a missed diagnosis of an occult early invasive 
cervical cancer for the VGX-3100 non-responders or placebo recipi[INVESTIGATOR_840], who do not regress. Serial 
cytology, HPV testing, and colposcopic exams are applied throughout the course of the study with the well 
accepted understanding that cervical dysplasia progresses s l  t i ally over years, which makes close, 
active follow-up possible.  All subjects will undergo excision  thera   EEP, LLETZ or CKC at Week 
36 as part of the efficacy assessment [ 18].  
Importantly, investigators in the HPV-[ADDRESS_449835] (DSMB) will also provide safety oversight as is being 
done for the HPV-[ADDRESS_449836] and/or central pathology 
laboratory for rapid local medical management. The definitive histopathologic assessment was determined 
by [CONTACT_360776]. Seven reports included the terms 
(adeno)squamous cell carcinoma’ or the premalignant condition of ‘adenocarcinoma in situ’ (AIS) in the 
final Phase 2b study results which included all 88 weeks of follow up. Three of the cases were reported as AIS, (2 VGX-3100, 1 placebo), out of which two cases (1 VGX-3100, 1 placebo) were confirmed as AIS 
by [CONTACT_360777]. AIS is a pre-invasive glandular lesion which can be difficult to capture 
on standard of care screening with initial punch biopsy and is more commonly identified by [CONTACT_360778] 
(e.g. LEEP, conization). There were four reports that included the term squamous cell carcinoma, of which 
two were confirmed by [CONTACT_360777], both in the VGX-3100 group. The other two 
cases (1 VGX-3100, 1 placebo) were diagnosed as CIN3 by [CONTACT_360777]. The rate at  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGroughouough
lowly, typi[INVESTIGATOR_360717], typi[INVESTIGATOR_360718] L therapy b
y will be chosen on be chose
n the HPVHPV -[ADDRESS_449837]
The DSMB will beDSMB will be
ising the Sponsor if ing the Sponsor if
s unacceptab y low acceptably low 
Y OF LONOF 
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  36of 87which micro-invasive cancer was found based on confirmed cases in larger surgical excision samples in 
subjects who had no evidence of invasive cancer by [CONTACT_360779]-3100+EP arm was 1.8%, (2/114 with specimens) and across both arms was 1.3% (2/155 with specimens), which is consistent with 
that reported under standard of care settings [ 19].  
In the HPV-003 study, all subjects were scheduled to be followed for approximately 1 year (Week 88) after 
the histopathologic assessment of the primary endpoint. The establishment of efficacy based on 
histopathologic evidence dictated the removal of tissue at Week 36 by [CONTACT_360780](ies) or more 
extensive surgical resection (i.e. LEEP, CKC). Investigators were instructed to perform a LEEP/CKC in 
subjects with colposcopic evidence of residual disease were to undergo LEEP/CKC. A higher proportion 
of patients who received placebo had a LEEP performed than those who received VGX-3100 (Table 10).
Cytology and HPV-16/18 clearance from the cervix was assessed at study Weeks 62 and 88 to evaluate for 
recurrence of dysplasia and HPV infection after removal of tissue at Week 36. Overall, in the Phase 2b 
study, the majority of subjects had improved cytology and had cl r d their underlying HPV-16/18 cervical 
infection by [CONTACT_56421] 62 and 88 visits. For Weeks 62 and 8  ere were no clinically meaningful 
differences noted between the subjects who received an excisional treatment (e.g. LEEP, CKC) and those that showed histopathologic regression and therefore only underwent a biopsy, as shown in Table 10 which 
summarizes the HPV and cytology results following Week 36   
Table 10:  HPV-003 HPV and Cytology R lt  at We  36, 62 and 88, mITT Population 
Week TestaVGX-3100 Placebo
LEEP/CKCb
%(n/N)Biopsyc
%(n/N)LEEP/CKC
%(n/N)Biopsy
%(n/N)
36 HPV 41% (19/46) 63% (36/57) 29% (6/21) 29% (5/17)
36 Pap NA NA NA NA
62 HPV 89% (50/56) 82% (42/51) 96% (27/28) 82% (9/11)
62 Pap 93% (52/56) 100% (51/51) 93% (26/28) 82% (9/11)
88 HPV 89% (48/54) 89% (42/47) 89% (24/27) 100% (10/10)
88 Pap 96% (52/54) 91% (43/47) 85% (23/26) 100% (11/11)
Abbreviations: NA, not applicable, Pap smear was not done at Week 36
a  HPV =  HPV-16/18 testing; Pap = cytology testing 
bLEEP or CKC done, at or before the study week as specified 
cOnly biopsy done, at or before the study week as specified
Clearance of HPV-16/18 from the cervix was observed in both treatment groups (Figure 1a) at similar rates 
until after the second dose when clearance in the VGX-3100 recipi[INVESTIGATOR_360719].
Figure 1: HPV-16/18 Clearance and Pap Smear Findings in Phase 2b mITT Population by 
[CONTACT_22059] -XQ  3URWRFRO _ 9970) _ 
52$SSURYHGcleareclea
and 88, thed 88, t
excisional treatme onal treat
nly underwent a biop nderwent a 
Week 36. 36. 
esults at Weeks 36ts at W
100RYBiops y Biopsycc
%(n/N) %(n/N)RYU46) 63% (36/5763% UUURSUNA NSUSUSUSSU89% (50/56) 50/56 8282SSSSSSSS93% (52/56 ) 93% (52/56)$SSS$S
89% (48/54)% (4$$$$$
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449838] of care. 
The protocol-specified removal of dysplastic cervical tissue at Week 36 by [CONTACT_360781]-16/18 and normalization of cytologic findings as expected, regardless of 
treatment group (Figure 1a, b) . HPV-16/18 clearance rises at a sharp rate after tissue is removed at Week 
36 whether the excision is wide (e.g. LEEP, LLETZ, CKC) or more limited (biopsy). Notably, the method 
of tissue collection at the Week [ADDRESS_449839] the HPV-16/18 clearance rates 
beyond Week 36 (T able 10 ). Based upon the Phase 2b results, the risk of recurrence of cervical dysplasia
and the risk of persistent High Risk HPV infection under these clinical trial conditions is lower than the 
rates observed post-LEEP/CKC in clinical practice. Fo r example, Xi et al. showed that in a prospective 
cohort of women with HPV-16 who participated in the ASCUS and LSIL triage study (ALTS), 6.0% (12/201) subjects had a recurrence of CIN [ADDRESS_449840]-LEEP [ 20]. In a very large 
retrospective cohort study (n = 3,273 women treated for CIN2, C N3, or AIS) Katki et al found, in the subgroup of patients who had an AGC, ASC-H, OR H I  etreat t screening result (n = 1,461 
women), a CIN2+ recurrence at [ADDRESS_449841]-treatment of 6.1% in wom n treated for CIN2 and 9.8% in 
women treated for CIN3 [21]. Nobbenhuis et al. have reported a rate  igh Risk HPV persistence of 14% (26/181) at [ADDRESS_449842]-LEETZ [2 2], as did Moore   h [ADDRESS_449843]-treatment (LEEP, cone, 
or laser ablation) persistence of: HR-HPV at 29.7% (260/874), HPV-16 at 14% (58/416), and HPV-18 at 
11% (11/99) [2 3]. 
The collection of cytology and virology da a f r  a onal year of follow-up after the removal of tissue 
at Week 36 was reassuring in that no significant recurrence of cytological or virological disease was noted. 
However, the removal of tissue at Week 36 did appear to obfuscate the differences between the treatment 
groups that were present at that time but normalized across groups after that visit presumably due to the removal of infected and/or dys tic tissue. A uming the longer term virologic and cytologic data 
collected in the companion HPV-301 Phase 3 stud  are similar to what was seen in the HPV-003 Phase 2b 
study, the collection of virologic nd or cytol c data beyond the Week 36 primary endpoint visit would 
not be expected to yield significant results in t is companion Phase 3 study.    -XQ  3URWRFRO _ 9970) _ 
$SSURYHG12 mon2 m
CIN2, CIN3,2, CIN3,
HSIL+ p men pretreat
ent of 6.1% n wome f 6.1% in w
e reported a rate of H orted a rat
Moore   h 12 m et al with 
9.7% (260/874), HPV (260/[ADDRESS_449844]  t su  ssu ic tissue. A
V-301 P1 Phase 3 studyase 3 study
ogic a /  nd/or cytologi
gnificant results in thificant results in t
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449845] meet all of the following criteria to be enrolled in the study:
1. Women aged 18 years and above that meet the minimum age of consent per local regulations;
2. Confirmed cervical infection with HPV types 16 and/or 18 at Screening by [CONTACT_360747]™ HPV test; 
3. Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis 
must be collected within [ADDRESS_449846] dose of study drug;
4. Histologic evidence of cervical HSIL as confirmed by [CONTACT_360782];5. Must understand, agree and be able to comply with the requirements of the protocol. Subjects must be 
willing and able to provide voluntary consent to participate and sign a Consent Form prior to study-related activities;
6. Must be judged by [CONTACT_343445]-specified procedure(s)  
required at Week 36;
7. Satisfactory colposcopy at Screening, defined as full visualization of the squamo-columnar junction 
(Type I or II transformation zone) and complete visualization of the upper limit of aceto-white 
epi[INVESTIGATOR_360711];
8. Cervical lesion that is accessible for sampling by [CONTACT_343448] (e.g. Mini-Tischler device);
9. Cervical lesion of adequate size to ensure that a visible lesion r ins after Screening biopsy;
10. Must meet one of the following criteria with respect to their rep oductive capacity:
a) Post-menopausal as defined by [CONTACT_343447] 12 months;b) Surgically sterile due to absence of ova ie  o  e t   bilateral tubal ligation/occlusion performed 
more than 12 months prior to screening;
c) Women of Child Bearing Potential (WOC  ar illing to use a contraceptive method with failure 
rate of less than 1% per year
awhen use  sistently and correctly from Screening until Week 36. 
The following methods are acce b e• Hormonal contraception: either com ed or progestin-alone including oral contraceptives, 
injectable, implants, vaginal ring, or percutaneous patches. Hormonal contraceptives must not be used in subjects with a history of hypercoagulability (e.g., deep vein thrombosis, pulmonary embolism);
• Abstinence from a nal intercourse when this is the subject’s preferred mode of sexual 
activity;
• Intrauterine device or intrauterine system;
• Male partner sterilizat  at least [ADDRESS_449847]’s entry into the study, 
and this male is the sole partner for that subject
11.Normal screening ECG or screening ECG with no clinically significant findings, as judged by [CONTACT_1275] .
a Use of condoms alone or condoms with spermicide does not have  a failure rate of <1% per year and is therefore not 
an acceptable form of contraception. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGvisualizationualizati
visualization of t ization o
biopsy instrument ( y instru
a visible lesion rema ble lesion r
respect to their reprect to th
neous amenorrhea fous amenorrh
ovaries or due to a b es or du
eening; g;
tial (WOCBP)WOCBP) arewi
when used consistenn used con
acceptable:
tion: either combin either com
ts, vaginal ring, or pe ginal ring, or pe
cts with a history of h h a history of h
rom penile -vaginal vaginal 
or intraur in
ion
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 40of 874.2 EXCLUSION CRITERIA
Subjects meeting any of the following criteria will be excluded from enrollment in the study:
1. Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal (inclusive of 
cervical HPV-related lesions that extend into the vaginal vault), or anal intraepi[INVESTIGATOR_360720];
2. Cervical lesion(s) that cannot be fully visualized on colposcopy due to extension high into cervical canal 
at Screening;
3. ECC that shows a potentially untreated carcinoma, untreated HSIL, indeterminate, or insufficient for 
diagnosis (ECC is not required to be performed as part of study screening);
4. Treatment for cervical HSIL within 4 weeks prior to Screening;
5. Pregnant, breastfeeding or considering becoming pregnant through Week 36;
6. History of previous therapeutic HPV vaccination (licensed prophylactic HPV vaccines are allowed, e.g. Gardasil™, Cervarix™);
7. Presence of any unresolved abnormal clinical screening laboratory values of Grade 1 or greater per 
Common Toxicity Criteria for Adverse Events (CTCAE) v 4.   emed clinically significant by [CONTACT_093] 60 days prior to Day 0;
8. Immunosuppression as a result of underlying illnes   reatment in ing:
a) History of or positive serologic test or IV  screening (performed within 60 days prior 
to Day 0)
b) Primary immunodeficiencies
c)/RQJ WHUP XVH   GD\V RI UDO RU SDUHQWHUDO JOXFRFRUWLFRLGV DW D GRVH RI  PJGD\ RI
prednisone equivalent; (use of inhaled, otic, and ophthalmic corticosteroids are allowed)
d) Current or anticipated use of disease modifying doses of anti-rheumatic drugs (e.g., 
azathioprine, cyclophosp  yclosporine, methotrexate), and biologic disease 
modifying drugs such as TNF- Į LQKLELWRUV HJLQIOL[LPDEDGDOLPXPDE RU HWDQHUFHSW
e) History of solid organ or bone marrow transplantation
f) Any prior history  other clinically significant immunosuppressive or clinically diagnosed 
autoimmune diseas  that may jeopardize the safety of the subject or require therapy that would inter  wit  s  sessments or endpoint evaluation, or otherwise impact the 
validity of the study results.
g) Subjects who  malnourished based on screening labs, medical history (e.g. clinically 
significant unintentional weight loss) and physical exam, as determined by [CONTACT_1697]’s
clinical judgment
9. Receipt of any non-study, non-live vaccine within 2 weeks of Day 0;
10. Receipt of any non-study, live vaccine (e.g. measles vaccine) within 4 weeks of Day 0;11. Current or history of clinically significant, medically unstable disease which, in the judgment of the 
investigator, would jeopardize the safety of the subject, interfere with study assessments or endpoint 
evaluation, or otherwise impact the validity of the study results (e.g. chronic renal failure; angina, 
myocardial ischemia or infarction, class 3 or higher congestive heart failure, cardiomyopathy, or clinically 
significant arrhythmias);
12. Malignancy or systemic treatment for malignancy within 2 years of screening (locally treated ano-
genital malignancy and superficial skin cancers are allowed); -XQ  3URWRFRO _ 9970) _ 
$SSURYHGlaboratoabora
v 4.   e03 and de
s or t  clud reatment in
for HIV at screeninHIV at scr
RUDO RU SDUHQWHUDO JOXRU SDUH
e of inhaled, otic, aninhaled, o
use of disease modof disease 
hosp am  cyclos hamide, c
ch as TNF--Į LQKLELWRĮLQK
rgan or bone marrow r bone m
y of   other clinically
diseas  that may j e that may jeo
r   sfere with study as
of the study results.e study results.
who are malnour are maln
nintentionaltent
tt
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 41of 874.2        EXCLUSION CRITERIA (continued)
13. Presence of acute or chronic bleeding or clotting disorder that would contraindicate intramuscular (IM)
injections, or use of blood thinners (e.g. anticoagulants or antiplatelet drugs) within 2 weeks of Day 0;
14. History of seizures unless seizure free for 5 years with the use of one or fewer antiepi[INVESTIGATOR_125796];
15. Sustained, manually confirmed, sitting systolic blood pressure >150 mm Hg or <90 mm Hg or a diastolic 
blood pressure >95 mm Hg at Screening or Day 0;16. Resting heart rate <50 bpm (unless attributable to athletic conditioning) or >100 bpm at screening or 
Day 0;
17. Prior major surgery within 4 weeks of Day 0;
18. Participation in an interventional study with an investigational compound or device within 30 days of 
signing informed consent; participation in an observational study is permitted;
19. Less than two acceptable sites available for IM injection onsidering the deltoid and anterolateral 
quadriceps muscles;20. Tattoos, keloids or hypertrophic scars located within 2 cm of intended treatment site;
21. Cardioverter-defibrillator or pacemaker (to preven   life-threatening arrhythmia) that is located in 
ipsilateral deltoid injection site (unless deemed acceptable by a cardiologist);
22. Metal implants or implantable medical device wit  t  lectroporation area;
23. Active drug or alcohol use or dependence that, in the opi[INVESTIGATOR_871], would interfere with adherence to study requirements;
24. Prisoner or subject who is compulsorily detained (involuntarily incarcerated) for treatment of either a 
psychiatric or physical (i.e. infectious disease) illness;
25. Active military service personnel;
26. Study-related staff or family member of study related staff;27. Any illness or condition that in t e op nion of the investigator may affect the safety of the subject or the 
evaluation of any study endpoint.
4.3 DISCONTINUATION/WI AWAL OF STUDY SUBJECTS
Subjects who manifest Grade [ADDRESS_449848] on the 
importance of maintaining the assigned visit schedule for follow-up and treatment of HSIL (CIN2, CIN3), 
to ascertain whether or not the subject wishes to and/or should continue in the study based on previous 
noncompliance. In cases where the subject does not return for the rescheduled visit or cannot be reached to  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGn c
cm of intendedof intende
t a life -threatening threaten
able by a cardiologis by a cardio
within the electropora n the electr
t, in the opi[INVESTIGATOR_360721] (involuntarned (in
ase) illness;illnes
ber of study f study --related srel
he opi[INVESTIGATOR_360722]
N/WITHDRAWA THDRAWA
rade [ADDRESS_449849]
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449850] ([ADDRESS_449851]’s last known mailing address). If these attempts to contact [CONTACT_360783] (i.e. lost to 
follow-up). If contact [CONTACT_360784]-established, the site should contact [CONTACT_360785]-up visits for the study. For all other 
subjects withdrawing from the study, an alternative reason for discontinuation should be recorded in the eCRF. 
The investigator or study coordinator must notify the Sponsor within [ADDRESS_449852] has been 
discontinued/withdrawn due to an AE. If a subject discontinues from the study or is withdrawn from the study prior to study completion, all applicable activities scheduled for the final study visit should be 
performed at the time of discontinuation. The investigator will make every effort to have all scheduled 
blood samples collected as indicated in the Schedule of Events in Table 1 . Any AEs and/or SAEs present 
at the time of discontinuation/withdrawal should be followed in accordance with the safety requirements 
outlined in section 7.1 – Safety Parameters.
The primary reason for a subject discontinuing further do n  o  thdrawal from the study itself is to be 
selected from the following standard categories and recorded on the CRF:
• Adverse Event (Adverse Reaction): Clinical or laboratory events occurred that, in the medical judgment 
of the investigator for the best interest of the subject, are grounds for discontinuation. This includes serious 
and non-serious adverse events regardless of relation to study drug. 
xDeath of subject, (including manner of de th if known)  
xSubject voluntarily withdrew consent: The subje  sir d o withdraw from further participation in the 
study in the absence of an investiga -determ d me ical need to withdraw. If the subject gave a reason for withdrawal, it must be recorded on he CRF. This reason does not allow for further data 
collection and should not be selected if foll -up data collection of this subject is anticipated by [CONTACT_1560]. 
xInvestigator decision to with  e t rom participation: Investigator determined a medical 
need to withdraw the s t. tig or must consult the Sponsor’s Medical Monitor before 
withdrawing a subject rom participation n the study. 
xProtocol Deviation: T  bject’s findings or conduct failed to meet the protocol entry criteria or failed 
to adhere to the protocol requirements (e.g., treatment noncompliance, failure to return for defined 
number of visits). The deviation should be discussed with the Sponsor’s Medical Monitor prior to 
discontinuation of study treatment  or study withdrawal. 
xLost to Follow-up: The subject fails to attend study visits and study personnel are unable to contact [CONTACT_360786], letter sent by [CONTACT_360787]. 
xOther: The subject was terminated for a reason other than those listed above, such as the termination of 
the study by [CONTACT_1034]. 
If more than 10% of subjects from randomization of study treatment discontinue prior to the Week 36 primary endpoint procedures, then supplementation of study subjects will be considered.  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGsing or withdr or withdr
rded on the CRF: n the CR
oratory events occurr y events oc
t, are grounds for dis grounds fo
tion to study drug.to study dr
ath if known) f known)  
The subject desired to bject de
tor-determined medetermined 
recorded on the CR ded on t
ected if follow if follow --up da
hdraw the subject fw the subject 
ubject. Investigator . Investigator 
from participation in om participation i
he susuject’s findingject’s findingbb
ocol requirements requirem
deviation shoatio
tments
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 43of 875 STUDY TREATMENT
5.1 INVESTIGATIONAL PRODUCTS
The active and placebo formulations to be used in this study are described in Table 11. Both Investigational 
Products (IPs) will be presented in clear glass cartridges and injected intramuscularly.
VGX-3100 and placebo will be provided by [CONTACT_343423], Inc. or its designee.
Table 11:  Investigational Products
Product Formulation Dose
VGX-[ZIP_CODE] mg (1:1 mix of SynCon™HPV-16 E6/E7 and HPV-18 E6/E7 plasmids) in [ADDRESS_449853]’s treatment assignment in case of an emergency or serious 
medical condition when knowledge of the stud  tr atm nt is es ential for proper clinical management of 
the subject, as judged by [CONTACT_093]. It is preferred, b  t required, that the investigator first contact 
[CONTACT_360788]’s treatment assignment. In case of 
non-emergency, investigator must co  Medical Mo or to discuss the options before unblinding the 
subject’s treatment assignment. 
The Sponsor’s or designee’s pha a i e t f  may unblind the treatment assignment for any subject 
with an SAE, UADE, or AE of t. N  pe s nel directly involved with the study will be unblinded. If 
expedited regulatory reporting is required   event, the report may be submitted to regulatory authorities 
with the subject’s treatment assignment  in accordance with local regulations. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGMGhroughout the studyghout the s
o difference in appea erence in ap
ct’s treatm nt assignmeatment a
udy treatment is esstreatme
t is preferred, but no referred, b
before unblinding thre unblindin
ntact a  onit Medical M
rmacovigilance staff ovigilance sta
f interest. No person rest. No person
ng is required fng is required f or an offf
nt assignment, in acassignment, in ac
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 45of 87 -XQ  3URWRFRO _ 9970) _ 
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 46of 875.4 TREATMENT REGIMENS
The three-dose regimen of VGX-3100 appeared to be safe and well tolerated in the HPV-003 study, 
therefore all eligible subjects who consent to participate in the HPV-303 study will receive three 6 mg doses of VGX-3100 or placebo administered in 1 mL IM (deltoid, preferred site, or anterolateral quadriceps, 
alternate site), each followed immediately by [CONTACT_151657]™ 5PSP device. The first study 
treatment will be administered on Day 0, the second at Week 4, and the third (final) study treatment will be 
administered at Week 12. The first study treatment will be given as soon as possible following confirmation 
of the cervical HSIL diagnosis and HPV-16/[ADDRESS_449854]’s biopsy specimen used for diagnosis by [CONTACT_360789], concurrent with the positive 
testing for HPV-16/18.
5.5 PACKAGING AND LABELING
Each cartridge will be labeled with a single-panel label and then individually packaged within a pouch that 
will contain an additional, double-panel label with tear-of . Bo h VGX-3100 and placebo labels will include, at minimum, the following information in Table 12:   -XQ  3URWRFRO _ 9970) _ 
f. th Bo
2: 
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 48of 875.6 HANDLING AND STORAGE
The CELLECTRA™ 5PSP device and its components must be stored in a secure location according to the 
instructions in the User Manual. For the specific temperature guidelines for storing, please refer to the CELLECTRA™ 5PSP User Manual. Inovio Pharmaceuticals, Inc. will be responsible for assuring the 
quality of the IP is adequate for the duration of the trial. Unless otherwise specified, IP will be shipped in a 
refrigerated condition with a temperature monitoring device. If the temperature monitoring device records 
temperatures outside the pre-specified range for any product, the Sponsor, or its designee should be contact[CONTACT_15608].
Immediately upon arrival, IPs should be transferred from the shippi[INVESTIGATOR_343353] 2–8 °C (36-46 °F) 
storage, in a secure area, according to local regulations. The Sponsor should be notified of any deviations 
from this recommended storage condition. 
Refrigerator temperature logs must be maintained at the clinical site and temperatures must be recorded and 
monitored regularly.
5.[ADDRESS_449855] not be discarded until:
1) Administration is completed and 
2) All pertinent information fro  the pouch label has been documented in source. 
The product must be used within [ADDRESS_449856] be discarded after reconciliation.
5.8 USE OF CELLECTRA™ 5P P DEVICE
The instructions for use of  E LECTRA™ 5PSP are located in the CELLECTRA™ 5PSP User 
Manual. Users of the CELLECTR  5PSP device must successfully complete training before using the 
device. Training will include review of the entire device User Manual as well as hands-on training. After 
training on the proper use of the CELLECTRA™ 5PSP device, the intended users at each site will be 
required to demonstrate their competency in its use to Inovio personnel or its designee. An instructional video has been prepared for review by [CONTACT_360790].
The treatment procedure must be performed by [CONTACT_5944]. Any individual designated to perform 
the procedure should be permitted by [CONTACT_343480] (e.g. MD, DO, RN) in addition to successfully completing device training from Sponsor personnel. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGat the IP is only disp  IP is only 
rized personnel acco personne
move the pouch froe the p
t not be removed fro be remove
ed and nd 
n from the pouch lab m the pouc
in 4 hours of removhours of remov
ed after reconciliati er reconciliati
CTRA A™™5PSP 5PSP DEDE
theCELLECE
RA™R
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449857] comply with applicable regulations and guidelines, and 
should include:
xAmount received and placed in storage area;
xAmount currently in storage area;
xLabel ID number and use date or expi[INVESTIGATOR_5695];
xDates and initials of person responsible for each investigational product inventory/movement;
xAmount dispensed to each subject, including unique subject identifiers;
xAmount transferred to another area/site for dispensing or storage;
xAmount returned to Sponsor;
xAmount destroyed at study site, if applicable.
5.9.2 CELLECTRA™ 5PSP DEVICE
The site is responsible for maintaining the device and its account  logs. The device must have full 
traceability from receipt of the components through the device   return of the device. The site must 
document acknowledgement of receipt and then notify Inovio upon eceipt of the device. This includes the content shipped and condition of the items upon r  
For each subject treatment, there must be  or  f each p o ct used for that subject, i.e. CELLECTRA™ 
5PSP Base Station & Handset serial number  ay  number and the study drug lot number. The used 
Array attachment must be disposed of in accordance with institutional policy regarding disposal of sharp 
needles/instruments.
5.[ADDRESS_449858] be destroyed at site per institution policy 
or returned to Inovio Pharmaceuti ls, Inc. or its designee, if site cannot destroy IP. 
The used IP cartridge will be discarded along with the disposable array within a Sharps container at site.It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. The 
return of unused IP(s) should be arranged by [CONTACT_20459].
The unused IP can only be destroyed after being inspected and reconciled by [CONTACT_360791], Inc. personal or designated Study Monitor.
If IP is returned to Inovio Pharmaceuticals, Inc., or its designee, it must be accompanied by [CONTACT_282636]. Returned supplies should be in the original containers. Empty containers should not be  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGand its accountability ts account
gh the devicedevice use, tous
notify Inovi  upon rfy Inovio
on receipt.
a record of each produ rd of each p
umber, , AArrayrr lot numl
of in accordance wit accordance
STRUCTION OFRUCTION OF
IGATIONAL PRGATIONAL PR
ination of the studon of the
ceuticals, Intica
d
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  50of 87returned to Inovio Pharmaceuticals, Inc. The return of unused IP(s) should be arranged with the responsible 
Inovio personnel and/or Clinical Monitor. 
5.10.2 CELLECTRA™ 5PSP DEVICE
Upon completion or termination of Inovio’s studies, the Base Station and Handset must be returned to 
Inovio Pharmaceuticals, Inc. Device components returned to Inovio Pharmaceuticals, Inc. must be 
accompanied by [CONTACT_360792]. Returned supplies should be in the original 
containers. The return of all device components identified above should be arranged by [CONTACT_360793].
Unused 5PSP Arrays may be either returned to Inovio or destroyed on site.  If destroyed on site, it is the 
investigator’s responsibility to ensure that arrangements have been made for the disposal. 
xWritten authorization must be granted by [CONTACT_360794], Inc., or its designee of the disposal,  
xEnsure that proper procedures for disposal have been esta d and followed according to applicable 
local regulations, guidelines and institutional procedures,  
xAppropriate records of the disposal have been documented.
6 STUDY PROCEDURES AND S DUL
This section lists the procedures and param  for each planned study evaluation. The timing of each 
assessment is listed in the Schedule of Events Table (see Table 1 ).
A subject will be required to provide informed consent for use of any information collected prior to 
consenting and before any additional study spe ific procedures are performed. Results and activities 
performed as part of the screening process in the HPV-[ADDRESS_449859] of care biopsy results of CIN 1/2, CIN 2, CIN 2/[ADDRESS_449860] biopsy 
slides or tissue sent to the central pathology lab for review by [CONTACT_360795].  
Figure 7 below illustrates the information in order of priority that could help in the identification of 
potential subjects for screening. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGut
al i s hd  blishe
es, 
mented.
CH D LEEDUL
eters  for each planneeach pl
ntsTable bl(s ee Table 
nformed consent for u d con
study specy spec ific proceific p
proce    HPV ss in the 
activities for HPV-3 ities for HPV-
303 screening. Partic creening. Partic
sults be applied to Hsults be applied 
articipation in HPV-3cipation in HPV-3
ions w ll not bewill 
Adherencdhe
ire
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449861] treatment adverse event and injection site reaction evaluation
xReview Week 4 PDC (after reviewing the PDC and post treatment injection assessment with the subject 
on the phone, the investigator or study personnel will determine whether an office visit is needed for 
further evaluation)
WEEK 8 (±4 DAYS)
The following study evaluation will be performed during the visit :
xTargeted physical assessment
xVital signs
xCollect and review PDC for dose [ADDRESS_449862] treatment adverse event and injection site reaction evaluation
xThinPrep™ sample for HPV typi[INVESTIGATOR_360723] (subject should be requested to abstain from any 
sexual activity and refrain from use of douching or vaginal lubricants/medication for a period of 24 hours prior to sample collection)
WEEK 12 (±4 DAYS)
The following study evaluation will be performed on We   rior to study treatment :
xTargeted physical assessment
xVital signs including weight
xUrine pregnancy test
xStudy treatment will be administered 
The following study evaluations will be performed at Week [ADDRESS_449863] treatment :
xPost treatment adverse event and nje on te tion assessment within a minimal of 30 minutes after study treatment
xDistribute PDC
**Please remember to download EP data from device within 24-48 hours of study treatment. **
8-[ADDRESS_449864] DOSE 3 PHONE CALL
The following informatio  wil  b  evaluated during phone call :
xPost treatment adverse event and injection site reaction evaluation
xReview Week 12 PDC (after reviewing the PDC and post treatment injection assessment with the subject on the phone, the investigator or study personnel will determine whether an office visit is needed 
for further evaluation.)
WEEK 15 (± 1 WEEK)
The following study evaluations will be performed at Week 15 :
xTargeted physical assessment
xVital signs
xPost-treatment injection site reaction assessment
xUrine pregnancy test -XQ  3URWRFRO _ 9970) _ 
$SSURYHGd on Week [ADDRESS_449865] DOSE 3 P
n will be evalu l be 
and i
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449866] be in accordance with applicable regulations and Good Clinical Practice (GCP). Qualified study personnel will meet with prospective study participants, explain the study, 
and provide them with an informed consent form (ICF) that describes the screening tests, eligibility criteria for entering the study, study treatments and follow-up procedures, in a language understandable to the 
subject. Explanation of the study includes, but is not limited to, study objectives, potential benefits and 
risks, discomforts/inconveniences, and the subject’s rights and responsibilities. The subject or subject’s legally acceptable representative is then requested to sign and date the ICF. A copy of the signed informed 
consent documentation must be provided to the subject or subject’s legally acceptable representative. The 
qualified study personnel will document the process of obtaining informed consent within the source record. 
Signed ICFs are maintained in the subject’s source records and must be accessible for verification at any time. 
6.[ADDRESS_449867] identification number (SID), which identifies 
the subject for all study-related procedures. Once assigned, SID  ot be reused for any reason. Information regarding the SID and screen date ill  ocu e  on a screening and enrollment 
log/system and in the eCRF.
Subjects meeting eligibility criteria listed in the protocol will be randomized by a computer-generated 
allocation schedule. 
6.4 SAFETY EVALUATIONS
6.4.1 PHYSICAL EXAMINATION
A complete physical examination (P  i   nducted during screening and study discharge.  It will 
include an assessment of the following: general appearance, skin, head, eyes, ears, nose, and throat, lymph 
nodes, respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, genitourinary, musculoskeletal, and neurological 
systems. 
A targeted physical assessment will be performed at other visits as determined by [CONTACT_360796]. 
6.4.2 VITAL SIGNS
Vital signs will be measured at specified visits and will include:
xSitting systolic and diastolic blood pressures with subject sitting at rest for at least 5 minutes before 
measurement
xRespi[INVESTIGATOR_360724] 
6.4.3 HEIGHT AND WEIGHT
Height and weight will be collected at Screening and on Day 0, Weeks 4 and 12.  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGON NUMN NU
ect identificationentificati
assigned, SIDs cann ned, SIDs 
will be documented docum
the protocol will be rotocol w
NATION IO
on (P  i   n E) will be co
following: general ap ing: general ap
vascular, gastrointesascular, gastroint
sment will be p t w
s
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449868] and present conditions at screening, as well as prior surgical procedures will be recorded 
for the main body systems (as judged by [CONTACT_093]). The medical history will include 
a) Any prior history of CIN diagnosed – with diagnosis date(s) and respective CIN 
level(s),
b) If treated previously for CIN, the respective treatment type(s) and date(s).
6.4.5 SOCIO-BEHAVIORAL ASSESSMENT
Socio-behavioral assessment, including self-reported smoking history, history of exposure to second-hand 
smoke, alcohol intake history, recreational drug use, contraceptive use and type of contraceptive if known, 
reproductive history, history of prior cervical dysplasia, and pregnancy history will be obtained at 
Screening, Weeks 36 and 40. Socio-behavioral assessmen    erformed to document any change 
from Screening.
6.4.6 LABORATORY EVALUATIONS
At Screening, blood samples will be taken to be te  o  serum chemistry and hematology:
Complete blood count (CBC) :
• White blood cell (WBC) count with differential
• Red blood cell (RBC) count
• Hemoglobin, Hematocrit
• Platelet count 
Serum Chemistry :
• Albumin
• Glucose
• Serum glut c-pyruvic transaminase (SGPT)/Alanine aminotransferase (ALT)
• Blood urea nitro  B N)• Creatinine
• Electrolytes (Sodium, Potassium, Chloride, Carbon Dioxide or Bicarbonate)
• Creatine Phosphokinase (CPK)
6.4.7 URINALYSIS (UA) 
Urine samples will be tested at screening by [CONTACT_112649], protein, and hematuria. If abnormal 
(presence of protein, KHPDWXULD RUJOXFRVH  DPLFURVFRSLFH[DPLQDWLRQVKRXOG EH SHUIRUPHG 
6.4.8 DEMOGRAPHICS
Demographic information will be collected via self-report (unless noted otherwise), including the following:
xAge
xRace/ethnicity -XQ  3URWRFRO _ 9970) _ 
$SSURYHGnd pnd 
ts   pwill be
S
sted f  orserum chemserum c
nt with differential h differe
amicc--pyruvic transampyruvic transam
nitro  ) gen (BUN
um, Potm
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449869] as well as an investigator assessment of whether the ECG is normal or 
abnormal (automated interpretations of ECG should not be used). Abnormal ECGs should be interpreted as 
“clinically significant (CS)” or “not clinically significant (NCS)” by [CONTACT_093].
6.4.[ADDRESS_449870] (PDC) SUBJECT SELF EVALUATION
Subjects will be provided and trained on a PDC and w   a k d  r cord the following the evening of 
study treatment through Day 6:
xOral temperature and time taken (before 11:59 pm)
xGeneral symptoms of feeling unwell
xPain and itching at injection site
xMeasure redness, swelling, bruising at injection site
xMedications taken
The completed PDC will be reviewed wit   subject by [CONTACT_360797] [ADDRESS_449871]-dose phone 
call and at the next in-person visit.
The study staff will review the P C fo  g r  mptoms (e.g. malaise, fatigue, headache, nausea, and 
myalgia/arthralgia), injection ite  y p oms (e.g. pain, erythema and edema), medical events and medications. 
Any PDC entry determined to meet the TCAE criteria for a Grade [ADDRESS_449872]’s ongoing medical history. If the PDC
entry does not meet the criteria o  a rade 1 or higher AE as per the CTCAE guidelines, clinical judgment 
can be used to determine whether the entry should be recorded as an AE and documented accordingly in 
the site’s source. For cases where the PDC entry and final AE reporting (i.e. grading) do not agree, the reasoning should be recorded in the source documents.
6.4.12 PAP SMEARS AND HPV TESTING
Pap smears will be obtained using ThinPrep™ test kits at screening, Day 0, Weeks 8, 15, 28 and 36. They will be sent to and read in a central laboratory. HPV PCR by [CONTACT_360747]™ HPV test will be performed on the 
ThinPrep™ specimen. At each of these visits, menstrual cycle status & recent history will be collected via 
self-report. If the Pap smear result suggests progression to cancer at Day 0, Weeks 15, 28 or 36, the 
investigator may schedule an ad hoc visit to perform a colposcopy and possible biopsy if clinically 
indicated. -XQ  3URWRFRO _ 9970) _ 
$SSURYHG)
C)SUBJECUBJE
ill be ask d to recore asked to r
9 pm) )
injection sitection site
d with the su ject by h the subje
e PDC for general sy C for general s
n site reaction sympto eaction sympto
ed to meet the meet th CT
ent less dun
f a Grf
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449873] will be requested to abstain from any sexual activity and refrain from use of douching or vaginal 
lubricants/medication for a period of 24 hours prior to collection of ThinPrep™ samples to eliminate 
potential interference with the results of HPV testing.  
At visits (i.e. Screening, Day 0, Weeks 15, 28 and 36) where multiple cervical samples are collected, the 
two digene™ cervical brushes will be collected prior to the ThinPrep™ sample.  
 
Details of sample collection and shipment information will be provided in the Laboratory Manual.
Additionally, if there is residual tissue available from cervical tissue from screening and Week [ADDRESS_449874] been rendered, then unstained slides and/or paraffin blocks may be collected to test for HPV typi[INVESTIGATOR_007]. Non-cervical swabs (vaginal and intra-anal) along with an oropharynx  
rinse will be collected at specified visits for HPV typi[INVESTIGATOR_007]. 
6.4.[ADDRESS_449875] be adequate, defined as full vis t  of the squamo-columnar junction 
(Type I or II transformation zone) and complete visualization of the u per limit of aceto-white epi[INVESTIGATOR_360725]. An ECC is not required for study entry. However, if an ECC was done as part of routine care during the screening period, and found to have evidence of cervical HSIL such subject should 
not be enrolled in the study. Colposcopy is not required to  er d at Screening if adequate colposcopy 
was previously obtained upon collection of initi l  l  colposcopi[INVESTIGATOR_360726] e  outli ed in Appendix A. 
Interval colposcopi[INVESTIGATOR_199886] a    W ks [ADDRESS_449876] of medical care would be to perform an unscheduled biopsy prior to Week 36, then his or her medical judgment should prevail over the default “Schedule of Events”, Table [ADDRESS_449877] of care and the 
investigator’s judgment based on the results of the histological diagnosis from the unscheduled biopsy. 
Additional instructions for collecting ectocervical biopsies are detailed in Appendix A . All biopsy 
samples/excised tissue will be sent to the central pathology lab for review by [CONTACT_360798].    -XQ  3URWRFRO _ 9970) _ 
$SSURYHGOSPSIE
ull vis al zation of ualization
ization of the upper on of the up
study entry. Howeve entry. H
d to have evidence o ave eviden
quired to be performe d to be p
initial biopsy.al biopsy. All 
he guidelines outline delines 
at Day 0, Weeks 15ay 0, Week
nvestigator if there itigator if th
CAL BIOP S BIOPSIE
ired at t SScreening to cening to c
erformed at any othformed at any ot
sue by [CONTACT_360799] y biopsy befor
e active or plactive 
b l a s se c
if
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  60of 876.5 INJECTION AND ELECTROPORATION (EP) 
Subjects will receive a 3-dose series of either 1 ml VGX-3100 or Placebo by [CONTACT_360800] (or 
anterolateral quadriceps muscle as an alternate option, if deltoid muscle is not possible or appropriate) 
followed immediately by [CONTACT_151657]™ 5PSP. Study treatment must not be given within 2 
cm of a tattoo, keloid or hypertrophic scar. If there is implanted metal, implanted device, within the same limb then use of the deltoid muscle on the same side of the body is excluded. 
6.6 MANAGEMENT OF ANXIETY AND PAIN DUE TO EP PROCEDURE
Subjects may be offered topi[INVESTIGATOR_15413] (e.g. EMLA or equivalent), to prevent significant discomfort 
from the treatment procedure. If a topi[INVESTIGATOR_343355], an approximately 1.5 cm diameter amount will 
be applied with occlusion to the site of injection ~30 minutes prior to treatment.  
Subjects may be offered a mild sedative (e.g. 0.5-1 mg lorazepam), or equivalent, for anxiety related to the 
treatment procedure. Mild sedatives may be administered approximately 1 hour prior to treatment at Day 
0, Weeks 4 and/or 12. Subjects who receive a mild sedative s ould  e allowed to operate a motor vehicle 
for 3-[ADDRESS_449878] arranged transportation to depart the study site.
Subjects may be offered an analgesic (e.g. ibuprofen, ket olac) after injection/EP. Subjects who are 
allergic to or have contraindications to EMLA, ibupr f  k olac  a mild sedative may be offered a 
suitable alternative. Medication taken for anxiety or pa  m na  should be added to the concomitant medications.
6.[ADDRESS_449879]’s CRF. 
6.9 ASSESSMENT OF INJECTION SITE REACTIONS
When evaluating injection site reactions throughout the study, the investigator will be instructed to use the following grading scale in Table 13 . -XQ  3URWRFRO _ 9970) _ 
$SSURYHGroximrox
hould not buld not
arranged transp ged trans
n, ketorolac) after in torolac) aft
rofen, oro  or a ketorolac
r pain management sn managem
Y ABNORMALIBNOR
hematology and seroatology and
med for inclusion into r incl
CAL STUDY ADL STUDY
ed by [CONTACT_360801]
s post study treatme study treatme
n a PDC.a PD  AnAnadversad
ueried regarding the ed regarding the 
ase, as well as coas well a
ately report y re
rom tho
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 63of 87The following medications and treatments are prohibited:
x/RQJ WHUP XVH   GD\V RI RUDO RU SDUHQWHUDO JOXFRFRUWLFRLGV DW D GRVH RI   PJGD\ RI SUHGQLVRQH
equivalent; use of inhaled otic and ophthalmic corticosteroids are allowed
xDisease modifying doses of anti-rheumatic drugs (e.g., azathioprine, cyclophosphamide, cyclosporine, 
methotrexate), and biologic disease modifying drugs such as TNF- Į LQKLELWRUV HJ LQIOL[LPDE
adalimumab or etanercept) at screening and throughout the study
xAdministration of any non-study related, non-live vaccine within 2 weeks of any study treatment or 
within 4 weeks of any study treatment for any non-study, live vaccine
xBlood thinners (e.g. anticoagulants, antiplatelet drugs) or other medication that affects blood clotting within 2 to 14 days (e.g., 4-5 drug half-lives) of any study treatment, biopsy or excisional procedure 
(e.g. LEEP)
The decision to administer a prohibited medication/treatment is done with the safety of the study participant 
as the primary consideration. When possible, the Sponsor should be notified before the prohibited 
medication/treatment is administered. All medications should  orded in the appropriate sections of the 
subject’s eCRF.
6.13
RESTRICTIONS
Subjects should not use alcohol or drugs that would interfere with study requirements during the course of 
the study and should report ALL medications/drugs taken to the investigator and/or other study personnel.
Subjects should refrain from becoming pregnant until [ADDRESS_449880] by [CONTACT_360802] (See Inclusion Criteria, Section 4.1). Lapses in 
contraceptive use should be reported to investigator and/or other study personnel.
Subject should abstain from sexual activity and refrain from use of douching or vaginal 
lubricants/medication for a period of 24 hours prior to collection of ThinPrep™ samples.
[ADDRESS_449881] potential disease progression. 
Subjects that undergo an early unscheduled biopsy will be classified as a non-responder in the efficacy 
analyses. These precautions should minimize the risk of progression of cervical HSIL. The increased frequency of close monitoring by [CONTACT_360803]. 
7.2 ADVERSE EVENTS (AES)
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or 
chemistry of the body, or worsening of a pre-existing condition, temporally associated with the use of a 
product whether or not considered related to the use of the product. In this study, such changes will be monitored, classified, and summarized, as Clinical or Laboratory AEs. Medical condition/diseases present 
before starting the investigational drug will be considered adverse events only if they worsen after starting  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGsh
d  orbe rec
d interfere ith study rfere with 
ugs taken to the inve aken to
nant until 6 months until 6 
ve measures as (See easures as
nvestigator and/or otigator and/
xual activity and activity 
of 24 hours prior to hours pri
F SAFETY AND FETY AND
METERS ERS
usio  in the Hn 
ent of ceo
ams
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 64of 87study treatment. Throughout the course of the study, all solicited and unsolicited AEs will be monitored 
and reported on an AE CRF, including the event’s seriousness, severity, action taken, and relationship to investigational product(s). AEs should be followed until resolution or stable and the outcome will be 
documented on the appropriate CRF. All AEs should be recorded in standard medical terminology rather than the subject’s own words.
AEs include the following:
xPre- or post-treatment complications that occur as a result of protocol mandated procedure during or 
after screening (before the administration of study drug).
xAny pre-existing condition that increases in severity, or changes in nature during or as a consequence 
of the study drug phase of a human clinical trial, will also be considered an AE.
xComplications of pregnancy; (e.g., spontaneous abortion, miscarriage, ectopic pregnancy, fetal death, still birth, congenital anomaly of the fetus/newborn); see Section 7.11 for additional information on 
pregnancy reporting.
xAll AEs that occur from when the informed consent is obtained onwards and throughout the duration 
of the study, including the follow-up off study drug p   be rded as an AE.
AEs do not include the following:
xMedical or surgical procedures (e.g., surgery, endosco , to t  raction, transfusion) performed; the 
condition that leads to the procedure is an AE
xPre-existing diseases or conditions or labor t r  n ities present or detected before the Screening visit that do not worsen.
xSituations where an untoward medica  o currence has not occurred (e.g., hospi[INVESTIGATOR_90676], social and/or convenience sions
xOverdose without clinical sequelae.
xAny medical condition or clinically significant laboratory abnormality with an onset date before the 
informed consent form is signed, is not an AE. It is considered to be pre-existing and will be documented on the medical his o y RF.
xUncomplicated pregnancy.
xAn induced elective abortion to terminate a pregnancy without medical reason.
7.3 SERIOUS ADVERS  VEN  (SAES)
A serious adverse event (SAE) is any AE that meets one of the following conditions:
xDeath during the period of surveillance defined by [CONTACT_760];
xIs immediately life-threatening (e.g., subject was, in the view of the investigator, at immediate risk of 
death from the event as it occurred). This does not include an AE that, had it occurred in a more serious 
form, might have caused death;
xAn event requiring inpatient hospi[INVESTIGATOR_360727] (even if the hospi[INVESTIGATOR_151605] a precautionary measure to allow continued observation. However, hospi[INVESTIGATOR_059] (including hospi[INVESTIGATOR_34096]) 
for a pre-existing condition that has not worsened, does not constitute an SAE;
xResults in persistent or significant disability/incapacity or substantial disruption of the ability to conduct 
normal life functions;
xResults in congenital anomaly or birth defect; -XQ  3URWRFRO _ 9970) _ 
$SSURYHGob nedtained on
eriod will be reco will be re
endoscopy, tooth ext copy, tooth
E.
ratory abnormalities y abnorma
al oc currence has nourrence h
admis o s). sions
ae.
nically significant lab significa
signed, is not an Aed, is not an 
al history RF. tory CRF
ncy.cy.
abortion to terminatetion to terminate
E EVENTSVE
any
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449882] and may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include:
oallergic bronchospasm requiring intensive treatment in an emergency room or at home,
oblood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], 
othe development of drug dependency or drug abuse or 
odevelopment of a malignancy
xIs medically significant or requires intervention to prevent one or other of the outcomes listed above.
Clarification of Serious Adverse Events:
xDeath is an outcome of an AE, and not an adverse event in itself.
xThe subject may not have been on investigational medicinal product at the occurrence of the event. 
xDosing may have been given as treatment cycles or interru te  temporarily before the onset of the SAE, 
but may have contributed to the event. 
x“Life-threatening” means that the subject was at immediate risk  eath from the event as it occurred. 
This does not include an event that might have led to death if it had o urred with greater severity.
xComplications that occur during hospi[INVESTIGATOR_182910]  e AE . I  a complication prolongs the 
hospi[INVESTIGATOR_059], it is an SAE.
xInpatient hospi[INVESTIGATOR_343360] a hospi[INVESTIGATOR_7521], for any length of time. This may or may not be overnight. It does not include presentation and 
care within an emergency department nor does it include full day or overnight stays in observation 
status.
The investigator will attempt to establish a diagnosis of the event on the basis of signs, symptoms, and/or 
other clinical information. In such cases, the diagnosis will be documented as the AE and/or SAE and not 
the individual signs/symptoms.
Serious adverse events that are ongoing should be followed until resolution or are clinically stable. The 
reporting period for SAEs is described in Section 7.15.3.
7.4 UNEXPECTED ADVERSE DRUG REACTIONS AND EXPEDITED REPORTING 
An adverse drug reaction (A )  ny noxious and unintended responses to a medicinal product related to
any dose; for which a causal rel tions ip between a medicinal product and an adverse event is at least a 
reasonable possibility; i.e., there is evidence to suggest a causal relationship between the product and the 
adverse event.  An adverse event or ADR is considered unexpected if it is not listed in the applicable product 
information (Investigator’s Brochure, Protocol, or User Manual) or is not listed at the specificity or severity 
which is consistent with the risk information provided. The Sponsor will assess each serious adverse drug 
reaction report for expectedness, to determine if it is a serious unexpected suspected adverse reaction 
(S[LOCATION_003]R) which requires prompt reporting to regulatory authorities and participating investigators as an 
expedited report, according to the applicable regulatory requirements. Additional occurrences of the 
S[LOCATION_003]R will be required to be reported on an expedited basis until the applicable product information is 
amended.
In addition to single-case reports of S[LOCATION_003]Rs, the Sponsor shall notify regulatory authorities and 
participating investigators of information that might materially influence the benefit-risk assessment of a  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGpd  te
ediate risk risk  eof dGo death if it had occath if it had
tions are AEs. If are AEs
ect has been formalhas bee
or may not be overni y not be o
nor does it include f oes it in
sh a diagnosis of t iagnosis he
ases, the diagnosis w the diagnos
e ongoing should begoing should be
described in Sectiondescribed in Se
ADVERSE DRUG ERSE DRUG
DR) is any no is a
ationshat
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449883] to the patient population, or a 
major safety finding from a study conducted in animals.  
7.5 UNANTICIPATED (SERIOUS) ADVE RSE DEVICE EFFECT (UADE)
Unanticipated adverse device effect means any serious adverse effect on health or safety or any life-
threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was 
not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with 
a device that relates to the rights, safety, or welfare of subjects. 
Per the definition above, a UADE is a type of serious adverse event (SAE) that requires expedited reporting 
on the part of the sponsor. As a reminder, all SAEs regardless of relationship to device, drug or procedure are to be reported to Sponsor by [CONTACT_63744] 4 hours. Sponsor will assess each device 
related SAE to determine if anticipated based on prior ide fi a ion in the investigational plan.
7.6 ASSESSING SEVERITY (INTENSITY)
Adverse events should be captured once on the CRF at t  m severity reported. 
The investigator will grade laboratory AEs wit  e ct   o ing levels of severity as defined in the 
document “Toxicity Grading Scale” for appli ble  po lations:
xMild (Grade 1)
xModerate (Grade 2)
xSevere (Grade 3)
xPotentially Life Threatening (Grade 4)
xDeath (Grade 5)
The investigator will grade c  Es or SAEs (based on discussions with study participants) in 
accordance with the Com n m ology Criteria for Adverse Events (CTCAE) v 4.03.
The investigator will grade injection site reactions in accordance with September 2007 FDA Guidance for 
Industry – Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials.
7.[ADDRESS_449884] a possible, probable or definite relationship to the 
administration of the IP and/or the device. An AE may also be assessed as not related to the investigational 
product and/or the device. Because the investigator is knowledgeable about the subject (e.g., medical history, concomitant medications), administers the IP, and monitors the subject’s response to the IP, the 
investigator is responsible for reporting adverse events and judging the relationship between the 
administration of the IP and EP and a subsequent AE. The investigator is aware of the subject’s clinical 
state and thus may be sensitive to distinctions between events due to the underlying disease process versus 
events that may be product related and may have observed the event. The Sponsor will assess the overall 
safety of the IP delivered by [CONTACT_343589]. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGof 
hin [ADDRESS_449885] to the
cable patient populae patien
Grade 4)de 4)
e clinical AEs or Se clinical AEs 
mon Terminology Crn Terminology C
injection site rcti
cale for Hle 
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449886], the circumstances surrounding the event, and 
an evaluation of any potential alternative causes to determine whether or not an adverse event is considered 
to be related to the IP and/or the device indicating "yes" or "no" accordingly. Causality should be assessed 
by [CONTACT_360804] (i.e. 
indiscernible) by [CONTACT_4868]:
xYes – there is a reasonable possibility that administration of the Study Treatment (drug or device 
or both drug and device) contributed to the event;
xNo – there is no reasonable possibility that administration of the Study Treatment contributed to 
the event and there are more likely causes.
The following guidance should also be taken into consideration:
xTemporal relationship of event to administration of IP and/or EP;
xCourse of the event, considering especially the effects of dose reduction, discontinuation of IP, or 
reintroduction of IP (where applicable);
xKnown association of the event with the IP, EP or with similar treatments;
xKnown association of the event with the disease under study;
xPresence of risk factors in the study subject or use of concomitant medications known to increase 
the occurrence of the event.
7.8 ABNORMAL LABORATORY VALUES
Laboratory abnormalities are usually not r c de   AE   AEs. However, laboratory abnormalities 
(e.g., serum chemistry, CBC, CPK, urinalysis) independent of the underlying medical condition that require 
medical or surgical intervention or lead t   upti n  discontinuation must be recorded as an AE, as 
well as an SAE, if applicable. In addition, laboratory or other abnormal assessments (e.g., 
electrocardiogram, x-rays, vital signs) that are associated with signs and/or symptoms must be recorded as 
an AE or SAE if they meet the definition of an AE (or SAE) as described in Section 7.1. If the laboratory abnormality is part of a syndrome, record the syndrome or diagnosis (e.g., anemia) not the laboratory result 
(e.g., decreased hemoglobin).
Any laboratory abnormality that is new in onset or worsened in severity or frequency from the baseline 
condition and meets one of the following criteria will be recorded as an AE:
xRequires therapeutic intervention or diagnostic tests
xLeads to discontinuation of study treatment
xHas accompanying or inducing symptoms or signs
xIs judged by [CONTACT_360805] 7.6.
7.[ADDRESS_449887] be reported for subjects on study (including any protocol-required post-treatment follow-up).
Investigators are not obligated to actively seek AEs or SAEs beyond the follow up period for subjects. 
However, if the investigator learns of an AE or SAE that occurs after the completion or termination visit  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGof
with similar tr similar t
 under study; study;
r use of concomitan of concom
LUE SS
ecorded as AEs or S ed as A
ysis) independent of t ndependen
to IP interruption or interruptio
In addition, laboraddition, l
ns) that are associate at are asso
efinition of an AE (otion of an A
me, record the syndro ecord the syndr
.
lity that is n w in o hat is new in o
f the following cfollowi
erventiorv
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 68of 87and the event is deemed by [CONTACT_343500], he/she should promptly 
document and report the event to the Sponsor.
7.[ADDRESS_449888].  Pr ncy Form will be completed by [CONTACT_360806]  r within 24 hours after learning of 
the pregnancy.  Site personnel will submit the Pregnancy Form to the Sponsor or its designee by [CONTACT_6791], as 
described in Section 7.15.3. The investigator will also report thi  e e  o the IRB/EC within [ADDRESS_449889]’s ission to query pregnancy outcome 
and follow each subject to determine the outcom  of the pregnan y. Results will be summarized in the 
Clinical Study Report (CSR). 
Subjects who become pregnant at any po  u ing e study will continue to be followed for safety 
assessments without receiving further IP. Procedures that are contraindicated during pregnancy, including 
additional treatments, must not be performed. In est ators should use clinical judgment regarding 
subsequent study-related blood collection based on the presence or absence of anemia in each subject. 
Subjects who are not withdrawn will continue to be followed for safety assessments to study discharge per 
protocol. 
All pregnancies that occu  o  he time of first study treatment through the follow up visits must be 
reported. The investigator w ll monitor the subject and follow the outcome of the pregnancy. If the end of 
the pregnancy occurs after the st   b en completed, the outcome will be reported directly to the study 
team and the Medical Monitor.
7.12 METHODS AND TIMING OF COLLECTION OF SAFETY DATA
Non-serious AEs and SAEs (and UADEs) will be collected for each subject from the time when informedconsent is obtained through Week 40.
The sources of AEs cover:
xThe subject’s response to questions about her health (a standard non-leading question such as ‘How 
have you been feeling since your last visit?’ is asked at each visit).
xSymptoms spontaneously reported by [CONTACT_423].
xEvaluations and examinations where the findings are assessed by [CONTACT_360807]. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGnant ftant a
A Pregnancy egnan
medic  r w al monito
ncy Form to the SpoForm to the
so report this event t ort this 
est th  t  perm e subject’s 
me of the pregnancof the p
oint during the stud during the
P. Procedures that ar cedures th
performed. Investigormed. Inv
llection based on th on based o
will contin e to be focontinue to 
r from the time of ffrom the time of 
r will monitor the sul monitor the su
the study has betudy ha
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449890]’s health becoming known to the investigator (e.g.,
hospi[INVESTIGATOR_059]).
All AEs will be reported on the appropriate CRF. Any SAE (or UADE) occurring during the course of the 
study must be reported to the Sponsor within 24 hours of awareness.
7.13 SAFETY AND TOXICITY MANAGEMENT
The Medical Monitor will be responsible for the overall safety monitoring of the study. 
Safety assessments include the following:
xIncidence of all adverse events classified by [CONTACT_9313] (SOC), preferred term, severity, 
and relationship to study treatment
xLocal and systemic injection site review; special atten n will be paid to the examination of the 
injection site. Administration site reactions and the s bject's complaints will be documented
7.[ADDRESS_449891] (AESI) are the adverse event  d related to VGX-3100/Placebo 
delivered with the CELLECTRA™ device that requi  expe i ed c munication from the site to the 
Sponsor and meet any of the following criteria:
xGrade 3 or greater persistent a GPLQLVWUDWLRQ VLWH HU\WKHPD DQGRU LQGXUDWLRQ UHFRUGHG   KRXUV
immediately after Study Treatment
x*UDGH  RU JUHDWHU SHUVLVWHQW DGP LVWUDWLRQ VLWH Q WHQGHUQHVV UHFRUGHG   KRXUV LPPHGLDWHO\
after Study Treatment
xGrade 3 or greater fever
xGrade 3 or greater systemic symptoms .g , malaise, chills, fatigue), including generalized pruritus
Sites will inform the Sponsor via the m  scribed in Section 7.15.[ADDRESS_449892] should continue.
7.15 ADVERSE EXPERIENCE (AE) REPORTING
To assure the safety of the participants, information about all AEs (see Section 7.2), whether volunteered by [CONTACT_423], discovered by [CONTACT_151703], or detected through physical 
examination, laboratory test or other means, will be collected and recorded in the subject’s source 
documents and followed as appropriate .
7.15.1
STUDY REPORTING PERIOD OF ADVERSE EVENTS
All solicited and unsolicited adverse events will be collected throughout the study and recorded in the EDC 
system. The Study Report will analyze and summarize all adverse events throughout the study. Emphasis 
will be placed on the following: 
xCertain AEs of interest will be solicited during the 7 days following each administration of Study 
Treatment and summarized separately
xUnsolicited AEs will be collected and summarized for the entire study period -XQ  3URWRFRO _ 9970) _ 
$SSURYHGtio
ub ect's bject
REST T
verse s d eme  events de
equire expedited com e expedite
VWUDWLRQ VLWH HU\WKHPLRQ VLWH
PLQLVWUDWLRQ VLWH SDLQWUDWLRQ VLWH
ic symptomsmptoms (e.g., m(e.
r via the method desr via the method
r th  p  e particular subje
ERIENCE (AEN
pant
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449893] (AESI) (see Section 7.14) require expedited communication from the site 
to the Sponsor. Within 24 hours of the site's awareness of the event, AESI must be reported by [CONTACT_360808] (eCRF) via the Medidata 
RAVE electronic data capture (EDC) system. In the event that the Medidata RAVE EDC system is unavailable, the investigator must notify the Sponsor via email or phone. 
AESI reporting if EDC system is unavailable
EMAIL:        
SAFETY PHONE:
7.15.3 STUDY REPORTING PERIOD OF S O S ADVERSE EVENTS
The reporting period for SAEs (without regard to caus ty  r la i ship) is comprised of the period 
following the signing of the informed consent form unt  the end of the study. 
Each AE will be assessed to determine whether it meets seriousness criteria. If the AE is considered serious, 
the investigator should report this event to the Sponsor within [ADDRESS_449894] operating 
procedures. Expectedness of SAEs will be determined by [CONTACT_941] S onsor using reference safety information 
specified in the Investigator’s Brochure.  t m y qualify for expedited reporting to regulatory 
authorities if it is an SAE, unexpected pe  reference safety information and considered related following 
the guidelines in Section 7.4 (Suspected Unexpected Serious Adverse Reaction, S[LOCATION_003]R) and 7.5 
(Unanticipated [Serious] Adverse evice  ine with  relevant legislation. All investigators will 
receive a safety letter notifying t  o all S[LOCATION_003]  reports. The investigator should notify the IRB/EC as soon as is practical, of serious events in w ting w ere this is required by [CONTACT_31665], and 
in accordance with the local institutional policy.  
Within 24 hours of the site's awareness of the event, all SAEs (regardless of relationship to investigational 
product) must be reported by [CONTACT_360809] (eCRF) via the Medidata R E electronic data capture (EDC) system.  In the event that the Medidata RAVE EDC system is unavailable, the paper SAE Report form should be used and faxed to the 
[COMPANY_003] Pharmacovigilance (PVG) Safety Hotline Fax Number shown below:
Facsimile (FAX) reporting if required
a: 
Americas FAX#:  
Europe FAX#:  
aReporting by [CONTACT_360810] (EDC) 
is not available, redacted supporting medi cal records, and Pregnancy Report Forms. 
All supporting documents for SAE reports, including medical records and diagnostic test results, will 
include reference to the study subject number. The study site will redact all other patient identifying  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGERIOUERIO
ality or relations r relation
il the end of the stud end of the 
ets seriousness criteeriousness
ponsor within 24 ho or within 24
event to the t to the IRB/E
etermined by [CONTACT_360811] b
An event may event ma qua
per reference safety ference saf
pected Unexpected d Unexpe
DeviceeEEffect)ffect in linin
hem of allallS[LOCATION_003]R reS[LOCATION_003]
events in writing whts in writing wh
nstitutional policy. ional policy.  
e's awareness of theawareness of the
d by [CONTACT_360812]
a RAVE elecAV
lable, ab
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  71of 87information present on SAE supporting documents prior to sending the report to the Sponsor. The 
supporting documents for SAE reports should be sent by [CONTACT_360813], 
shown above. 
Investigator will supply the Sponsor and the IRB/EC with more information as it becomes available and 
any additional requested information. The Sponsor or its representative will be responsible for determining and in turn, reporting SAEs to regulatory authorities according to the applicable regulatory requirements. 
SAEs must be followed by [CONTACT_117186], even if this extends beyond the study-reporting 
period. Resolution of an SAE is defined as the return to baseline status or stabilization of the condition with 
the expectation that it will remain chronic.
In the event of death, if an autopsy is performed, a copy of the report will be sent to the Sponsor. 
7.[ADDRESS_449895] of a clinical investigation. The Sponsor will n y ry agencies within the time frame 
specified by [CONTACT_360814]  10 worki  days for UADE, 7 days for a fatal or 
life-threatening S[LOCATION_003]R, and 15 days for a  ot er SUS s see Section 7.5 and 7.4). Results of 
investigations of other safety information s ll b  tted, as appropriate, in an information amendment 
or annual report. 
7.[ADDRESS_449896] complaint/device deficiency is defined as any written, electronic, or oral communication that alleges deficiencies or inadequacies of the device o  components related to the identity, quality, durability, 
reliability, safety, effectiveness, o  e f  of the device or components after it is released for 
distribution within the clinical investigation. All product complaints that meet this definition (with the exception of SAEs requiring 24 hr reporting) must be reported to the Sponsor with [ADDRESS_449897] be completed and emailed to the Sponsor at:
or fax to . 
7.18 STUDY DISCONTINUATION
Inovio Pharmaceuticals reserves the right to discontinue the study at this site or at multiple sites for safety 
or administrative reasons at any time. In particular, a site that does not recruit at a reasonable rate may be discontinued. Should the study be terminated and/or the site closed for whatever reason, all non-source  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGEVEEV
fy the apprope appr
ny adverse drug re verse drug
on that might materhat might m
onside  es in p r chang
will notify regulato notify regu
han 10 working da 10 wor
all oth  [LOCATION_003]Rs ( ther S[LOCATION_003]
hall be submitted, as e submit
CE RE ATED CORELATED
iency is defined as a is define
cies of the device or of the device o
ess, or performance r performance
ical investigation. Acal investigation. 
ing 24 hr reporting) 24 hr reporting) 
malfunctionsfunc
performer
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449898] on the primary endpoint is G= p V – p P, where p Vand p Pdenote the true biomarker-
positive population probabilities of the primary endpoint for VGX-3100 and Placebo, respectively. The 
primary hypothesis of superiority is:  
H0: Gd 0 vs. H1: G> 0.
A p-value for this hypothesis test and corresponding 95% confidence interval will be computed based on 
the method of Miettinen and Nurminen [17]. Superiority w   o uded if the one-sided p-value is 
<0.025 and the corresponding lower bound of the two-sided 95% CI exceeds zero.
The efficacy time frame is defined by [CONTACT_360815] g e  iopsy or surgical excision at any time 
starting from [ADDRESS_449899] no 
endpoint data for this time frame; these su  ar  s red as failures for the primary efficacy endpoints. Table 4 provides details for the definition of the primary endpoint response.   
The ITT biomarker-positive populatio   be p  r the analysis of efficacy in this study. Missing 
data will be considered as non-regr sso  ures) for the ITT efficacy analysis. Efficacy analysis using 
the mITT population will also be onduc   w  serve as sensitivity analyses regarding missing data
. 
The PP population will also be ed   s rtive analysis. An additional analysis on the PP population 
will utilize the Week 36 timefram   a dless of excision or biopsy performed before the Week 36 
time frame, thus serving as a sensitivity analysis regarding early intervention. Additional analyses will be 
performed on all subjects reg   arker status.
8.5.2 ANALYSIS OF THE SECONDARY ENDPOINTS
[IP_ADDRESS] Efficacy
The secondary efficacy endpoints will be analyzed in the same manner as the primary hypothesis, but 
without the hypothesis test p-values. The efficacy time frame is the same as for the primary endpoint.
Table 5 through Table 9  provide details for the definitions of the secondary endpoint responses. 
The ITT biomarker-positive population will be used for the analyses of these endpoints. Missing data will 
be considered as non-regressors (failures) for the ITT efficacy analyses. Efficacy analyses using the mITT 
population will also be conducted and will serve as sensitivity analyses regarding missing data .The PP 
population will also be used for supportive analyses.  Additional analyses on the PP population will utilize 
the Week 36 timeframe result regardless of excision or biopsy performed before the Week 36 time frame,  -XQ  3URWRFRO _ 9970) _ 
$SSURYHG0
confidence iidence
ty will be conclud be conc
sidedd95% CI exceed95% CI ex
ave undergone a biop ndergone a
fied  date of Wtarget d
Dose 1 but prior to th 1 but prio
subjects are conside cts are 
 definition of the prinition of th
on will be primary fo ill be prim
essors (failures) for s (failures)
conducted and will ducted and 
used for a supportiv for a supportiv
eframe  eg l result regardl
s a sensitivity analysa sensitivity analy
 reg   ardless of biom
OF THEF T
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 74of 87thus serving as sensitivity analyses regarding early intervention. Additional analyses will be performed on 
all subjects regardless of biomarker status.
[IP_ADDRESS] Immunogenicity
Post-baseline cellular and humoral response magnitude will be compared between treatment groups using a difference in medians and associated non-parametric 95% CIs.
Increases from baseline in interferon- Ȗ (/,6SRW UHVSRQVH PDJQLWXGHV DQG HPV E6 and E7 titers from 
ELISA at Weeks [ADDRESS_449900] to severity and 
relationship to Study Treatment. All serious AE  will also be summarized as above. 
The main summary of safety data will be based on events occurring within 14 days of any dose. For this 
summary, the frequency of preferred t m ts will be compared between study arms with risk differences 
and 95% confidence intervals, using the method of Miettinen and Nurminen [17]. As this analysis will use 
many event categories, and produce many confidence intervals, caution should be exercised when interpreting these confidence intervals. Separate summaries will be based on events occurring within [ADDRESS_449901] possible day 
consistent with the partial date.
AE duration will be calculated as (Stop Date – Start Date) + 1.
Analyses and summaries will be performed on biomarker-positive subjects and on all subjects regardless 
of biomarker status separately.
8.5.4
DISPOSITION
Disposition will be summarized by [CONTACT_360816], the number and percentage who received each dose and the number who completed 
the trial.  The number and percentage of subjects who discontinued will be summarized overall and by  -XQ  3URWRFRO _ 9970) _ 
$SSURYHGmunomu
atus.
populationlation by [CONTACT_360817]
y by [CONTACT_2715], and will d dose, and w
ts aff cted. dditionfected. A
relationship to Studyionship to S
lowing a worst g a wo -cas
ous AEs will also be AEs will also
ll be based on event based on e
d term events will bem events wi
ing the method of Mhe method 
produce many confuce many conf
e intervals. Separate s als. Separate s
 of when they occurf when they occur
dates ll be imp wi
ver the por th
ee a
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 75of 87reason. The number in each analysis population will also be presented. Summaries will be performed on 
biomarker-positive subjects and on all subjects regardless of biomarker status separately.
8.5.5 BASELINE CHARACTERISTICS
[IP_ADDRESS] Demographics
Demographic data will be summarized with descriptive statistics: mean standard deviation, minimum, 
median, and maximum values for continuous variables, and percentages for categorical variables, by 
[CONTACT_2939], for the ITT population. Summaries will be performed on biomarker-positive subjects andon all subjects regardless of biomarker status separately.  
[IP_ADDRESS] Medical History
The percentage of subjects with abnormal medical history findings will be summarized by [CONTACT_6764], by [CONTACT_2939], for the ITT population.  Summaries will be pe d on biomarker-positive subjects andon all subjects regardless of biomarker status separately.
[IP_ADDRESS] Prior Medications
Prior medications are those that were used before the start of the trial (prior to Day 0). Partial stop dates of prior medications will be assumed to be the lat t pos i l  ate sistent with the partial date; start dates 
will not be imputed. Data for all prior medications will be summarized with percentages by [CONTACT_2939], 
for the mITT population.  Summaries will be pe formed  bi marker-positive subjects and on all subjects regardless of biomarker status separately.
8.5.6
PLANNED INTERIM ANALYSES
No formal interim analyses will e pe f  f  this study. For reasons of futility (early evidence of poor efficacy of VGX-3100) or safety issues, the DSMB could recommend stoppi[INVESTIGATOR_360728]. The type I error of 0.05 will not  t d  le early stoppi[INVESTIGATOR_327578].
Group-level unblinded (VGX-3100, Placebo) summaries and analyses may be produced once the primary 
endpoint Week 36 visit da   completed for all subjects; subject-level blinding will be maintained. The 
summaries and analyses will allow e S onsor to have results with respect to the primary endpoint and key 
safety outcomes on which to make decisions regarding the VGX-3100 program while awaiting final 
database lock. The planned set of summaries and analyses is comprised of a) the primary composite 
endpoint of histopathologic regression and virologic clearance and b) adverse events of progression to cervical cancer.  Both will be performed on the biomarker-positive set of subjects and on all subjects. None 
of these summaries or analyses will be provided if the total count of subjects who experience the event of 
interest is greater than 0 and the count for any treatment group relative to this total count is less than 3% 
for a given summary/analysis. The group-level unblinded (VGX-3100, Placebo) production of the 
summaries and analyses will not include anyone directly involved with the trial or any additional unblinded personnel; only the external Contract Research Organization (CRO), [COMPANY_003], which has already been 
providing unblinded summaries for the Data Safety Monitoring Board, will be utilized. Thus, the trial will 
remain blinded with respect to subject treatment assignment throughout the trial. The type I error of 0.05 
will not be adjusted for this procedure. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGingsng
pe drforme
the start of the trial start of the t
est possible date con ssible da
ations will be summa s will b
be performed on bioerformed o
y.
ERIM ANALYSEM ANALY
be performed for this rformed for
ty issues, the DSMB ues, the DSMB
be adju e   sted for possib
VGX -3100, Placebo3100, Placebo
ta are completede comp
llow the Spw th
ake 
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 76of 878.5.7 SUBGROUP ANALYSES
Primary and secondary efficacy endpoints will be analyzed by [CONTACT_360818].
8.5.8 MULTIPLICITY
Not applicable, there is one hypothesis that will be tested.
8.5.9 MISSING VALUES
Missing data will be considered as non-regressors (failures) for the ITT efficacy analyses. A subject’s 
regression outcome is missing if the CIN grade and HPV clearance at the Week [ADDRESS_449902] who undergoes an unscheduled excision or biopsy in which cervical tissue 
sample is obtained after Dose 1 and before the Week 36 timeframe will be considered a non-regressor regardless of the Week 36 timeframe result. 
Efficacy analyses using the mITT population will be co t d and will serve as sensitivity analyses 
regarding missing data.
8.5.10
EXPLORATORY ANALYSES
[IP_ADDRESS] Efficacy
[IP_ADDRESS] Concomitant Medications
Concomitant medications are those used during the course of the trial (on or after Day 0). Partial stop dates 
of concomitant medications will be assumed to be the latest possible date consistent with the partial date; 
start dates will not be imputed. Data for all concomitant medications will be summarized with percentages by [CONTACT_2939], for the mITT population.
[IP_ADDRESS] Vital Signs
Measurements for vital signs as well as changes from baseline will be summarized with descriptive 
statistics: mean, standard deviation, minimum, median, and maximum values by [CONTACT_360819], for the safety population. Baseline is defined as the last measurement prior to the first treatment 
administration. -XQ  3URWRFRO _ 9970) _ 
HGnduc  a d ted an
ConcomCo
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 77of [IP_ADDRESS] Physical Examination
The percentage of subjects with abnormal physical examination findings at each time point will be 
summarized by [CONTACT_343514], for the ITT population.
8.6 SAMPLE SIZE/POWER
A sample of 198 subjects will be randomized to receive either 6 mg VGX-3100 or placebo IM followed by 
[CONTACT_343509] a 2:1 ratio.  This sample size provides >90% power to declare VGX-3100 superior to placebo among 
biomarker-positive women, utilizing the methodology described in Section 8.5.1, and assuming that the 
true proportion of subjects who achieve the primary endpoint is 66% and 15% for VGX-3100 and placebo, 
respectively, and that the proportion of biomarker-positive women is 33%. These proportions also 
incorporate missing data classified as non-regressors (failures) in accordance with the ITT analysis 
approach. The assumptions are based on the HPV-301 study results .
8.7 RANDOMIZATION AND BLINDING
Subjects will be randomized (2 VGX-3100:1 Placebo) in a stratifi d m nner according to a) the degree of 
&,1REVHUYHGLQWKHELRSV\VSHFLPHQVDWVFUHHQLQJ& &,1E%0,FDWHJRU\YV!NJP2)
on Day 0, and FDJHFDWHJRU\\HDUVYV\HDUV on Day 0. There will be no pre-determined number 
of subjects required to be randomized within each um. To ens  that milder CIN2 disease is not over-
represented in the study, the percentage of subjects enrolled with CIN2 will not exceed 50% of the total 
enrolled.  A group of sequential allocation nu b  i  b  e ig ted for use by [CONTACT_360820].
The study is double blinded. Randomization and blinding will avoid bias in the assignment of participants
to treatment, increase the likelihood that known and unkn wn subject attributes (e.g., demographics and other baseline characteristics) are even  balanced be en treatment groups, and enable valid statistical comparisons between treatment groups.
[ADDRESS_449903] OR ETHICS COMMITTEE (IRB/EC)
The investigator will undertake the study after full approval of the protocol and adjunctive materials (e.g., 
informed consent form, advertising) has been obtained from the applicable IRB/EC and a copy of this 
approval has been received by [CONTACT_1034].
Investigator responsibilities relevant to the IRB/EC include the following:
xDuring the conduct of the study, submit progress reports to the IRB/EC as required, and request re-
review and approval of the study at least once a year;
xNotify the Sponsor immediately of any suspected unexpected adverse drug or device events/effects;
xIf Sponsor notifies you about any reportable safety events notify the IRB/EC immediately; -XQ  3URWRFRO _ 9970) _ 
$SSURYHGn a stratified manne tified ma
,1YV&,1E%0YV&,1E
DUVon Day 0 on Day 0 . There . T
strat . To ure tum. To ens
jects enrolled with C enrolled
mbers will be des s will be des igna
on and blindnd blin ingingwill
at known and unkno own and un
enly balanced balanced betweb
oups.
AND SPONSOR ND SPONSOR 
sor are responsibre respo
ciples of tles 
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 78of 87xAs required, obtain approval from the IRB/EC for protocol amendments and for revisions to the 
consent form or patient recruitment advertisements;
xReports on, and reviews of, the trial and its progress will be submitted to the IRB/EC by [CONTACT_360821];
xMaintain a file of study-related information (see study files) that includes all correspondence with the IRB/EC;
xNotify IRB/EC when study is completed (i.e. after the last study visit of the final study patient);
xAfter study completion (within 3 months is recommended) provide the IRB/EC with a final report 
on the study.
9.3 IBC APPROVAL AND REPORTING
Investigator will ensure responsibilities relevant to Institutional Biosafety Committee (IBC) approval and 
reporting if applicable per local regulations.
9.4 ADDITIONAL APPROVAL AND REPORTING
The investigator and Sponsor are responsible for ensuring that the clinical study is reviewed and approved 
according to local and applicable global regulations (e.g. a  itutes of Health/Office of Science Policy) governing research that involves recombinant  n he  leic molecules.
9.[ADDRESS_449904] prior to enrollment into the study, and/or from 
the subject’s legally authorized representative. The process for obtaining informed consent must also be 
documented in the subject’s medical recor  ( e  S c on 6.2).    
9.5.2 COMPLIANCE WITH IRB /EC REQUIREMENTS
This study is to be cond  in accordance with applicable IRB/EC regulations. The investigator must 
obtain approval from a properly constituted IRB/EC prior to initiating the study and re-approval or review 
at least annually.  Sponsor is to be notified immediately if the responsible IRB/EC has been disqualified or 
if proceedings leading to disqualification have begun. Copi[INVESTIGATOR_28078]/EC correspondence with the 
investigator should be provided to Sponsor. 
9.5.3 COMPLIANCE WITH GOOD CLINICAL PRACTICE
This protocol is to be conducted in accordance with the applicable GCP regulations and guidelines. 
GCP regulations and guidelines include International Council of Harmonization (ICH) and International 
Organization for Standardization (ISO) and applicable local regulations.  
9.5.4 COMPLIANCE WITH ELECTRONIC RECORDS/SIGNATURES 
REGULATIONS (21CFR PART 11)
When applicable, this study is to be conducted in compliance with the regulations on electronic records and 
electronic signature. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGING
ring that the clinicalthat the clin
s(e.g. g.Nt ional Nationa Inst
nant   nuc or synthetic
ECTSTS
TH INFORMED C NFORME
ained from each subje from each 
presentative. ntative. The proThe
ical record (see Sectirecord (see 
ANCE WITH IRB WITH IRB
ucted in accordance ed in accordance 
roperly constituted ly constituted 
s to be notifiedbe n
ualificatali
Sp
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449905] be reported to the Medical Monitor immediately.  
9.5.6
CHANGES TO THE PROTOCOL
The investigator should not implement any deviation from or changes to the protocol without approval by 
[CONTACT_360822]/favorable opi[INVESTIGATOR_5698]/EC of a protocol amendment, except where necessary to eliminate immediate hazards to study subjects, or when the changes 
involve only logistical or administrative aspects of the study (e.g., change in monitors, change of telephone 
numbers). While every effort should be made to avoid protocol deviations, should a deviation be 
discovered, Sponsor must be informed immediately. Any prot  eviation impacting subject safety must be reported to the Medical Monitor immediately.  
[ADDRESS_449906]’s name [CONTACT_160491]. The subject’s name [CONTACT_360829], the 
governing health authorities or the Food and D ug Ad istration (FDA), if they inspect the study records. 
Appropriate precautions will be taken to maintain confidentiality of medical records and personal 
information.
Written authorization and other documentation are to be obtained from each subject prior to enrollment into 
the study, and/or from the subject’s legally authorized representative in accordance with all applicable laws, 
regulations or directives rel g  pr y d data protection.
11 SOURCE DOCUMENTS
Source data is all information, i i l ecords or clinical findings, laboratory results, observations, or other 
activities in a clinical trial neces y for the reconstruction and evaluation of the trial. Source data are 
contained in original source documents. Examples of these original documents, and data records include: 
hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subject’s diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_5117], microfiches, photographic 
negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the 
laboratories, and at medical records and within information technology systems that are involved in the 
clinical trial. The investigator/institution will permit trial-related monitoring, audits, IRB/IEC review, and 
regulatory inspections by [CONTACT_20618]/documents related to this study.
A medical history and history of medications must be present in the source documents. All prescription and 
nonprescription medications taken within [ADDRESS_449907] be provided. -XQ  3URWRFRO _ 9970) _ 
$SSURYHG docol
NG AND REPOAND RE
CY
ublished or sent to th ed or sen
lly marketed or may arketed
ments. The subject’s . The subj
and Drug A m istrDrug Admin
en to maintain cono maintai
documentation are to mentation are 
ect’s legally authoriz legally authoriz
ating to privacy and ting to privacy an
UMENTSENTS
ori al regin
sary
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449908] of the monitor, auditor, IRB/IEC, or regulatory authority, the investigator/institution 
should make available for direct access all requested trial related records.
CRFs will be provided for each subject. Subjects must not be identified by [CONTACT_68405]. Subjects will be identified by [CONTACT_343518] (SID).
It is the investigator’s responsibility to retain study essential documents for at least [ADDRESS_449909]. This retention period may be superseded by 
[CONTACT_318922]. The Sponsor will inform the investigator/institution as to when these documents are no longer needed to be retained.
[ADDRESS_449910] (DSMB) will provide safety oversight.  The DSMB 
will be scheduled to meet quarterly. If there are no new safety data or regression/clearance results to 
review for a quarterly scheduled meeting the DSMB will be notified and the meeting may be cancelled; 
ad hoc meetings may be scheduled to review new data as applicable. The DSMB will be charged with advising the Sponsor if there appear  to be a safety issue and with advising the Sponsor if it appears that 
the proportion of the subjects w h s  i  the VGX-3100 group is unacceptably low compared to the placebo group. However, no formal inter m analysis will be performed.
12.3 PATHOLOGY ADJUDICATION COMMITTEE
All histology slides (i.e. cervical biopsies or surgical excision tissue) will be read by a Pathology 
Adjudication Committee (P )  ensure consistent assignment of disease status for both study eligibility and the efficacy analysis. The PAC will consist of a total of four pathologists in separate 
locations. Each specimen will be read by [CONTACT_360823] a blinded fashion.  
12.4 CLINICAL MONITORING
Clinical monitoring of the clinical trial will be performed by [CONTACT_151699], who will report to 
the Sponsor or the Sponsor designee. Records for all clinical subjects in this trial will be monitored. 
Clinical site monitoring tasks will include but not be limited to the following at all sites:
xPrior to trial initiation, a site visit will be conducted to review all relevant forms and documentation, 
to ensure the site is qualified and compliant with all applicable requirements,
xAll clinical site monitoring visits will be documented,
xPeriodic site visits will be performed throughout the study, -XQ  3URWRFRO _ 9970) _ 
$SSURYHGGG
fter the last dose of V he last dos
inve   monstigators to
heduled biopsies if d led bio
G BOARDOARD
toring Bo  (DSMBng Board (D
. If th  are no new ere a
meeting the DSMB w ng the DSM
uled to review new d o review ne
appears to be a safety ars to be a s
cts with regression in th regression in
ver, no formaver, no forma l interil in
YADJUDICATIJUDICATIO
cervi l biovica
AC) toAC
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449911] 
activities and obligations and will:
oAssure that the study is being conducted in accordance with the protocol, applicable regulatory agency regulations, and IRB/EC policies,
oDiscuss study conduct issues and incidents of noncompliance with the investigator and/or study personnel and document them on the resolution trip report. Report any significant 
unresolved problems immediately to the Sponsor,
oRemind the investigator as necessary of the obligation to immediately report all serious 
adverse events (SAE) and provide subsequent follow-up report of the final outcome to the 
IRB/EC,
oThroughout the study, inspect all source documents to ensure they are attributable, legible, contemporaneous, original, accurate, and correct (ALCOAC),
oAssure that the study facilities continue to be acceptable,
oCompare the study CRFs with source docum nts to assure that the data are accurate and 
complete and that the protocol is being follow
oAssure that investigational drug and devic  ac  and reconciliation of records are 
complete and accurate,
oAssure that all subject specimens are being stored and forwarded properly for testing per 
Laboratory Manual requirements.
[ADDRESS_449912] 
and/or manuscript must be made available to the Sponsor [ADDRESS_449913] thirty (30) days afte  c t of the copi[INVESTIGATOR_360729]  t matter that needs protection. In the event that the Sponsor 
makes such objection, the res he ) shall refrain from making such publication or presentation for a maximum of three (3) months from t e date of receipt of such objection in order for patent application(s) 
(directed to the patentable subjec  er contained in the proposed publication or presentation) to be filed 
with the [LOCATION_002] Patent and Trademark Office and/or foreign patent office(s). -XQ  3URWRFRO _ 9970) _ 
$SSURYHGents
wedwed,,
e accountability ountabilit
being stored and forg stored an
CE
all p ar ing cou ticipat
t acc d g  he la ording to t
CY
s trial in its entirety l in its entiret
ade available o ailable to the Se S
30) days aft0) days aft er receiper rece
e is pat  patentable subjec
e res ar e ) sh earcher(s
s from the drom
t mattt
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449914]
ECG Electrocardiogram
eCRF E ectronic Case Report Form
ELISA Enz  n  Immunosorbent Assay
ELISpot Enzyme n ed Immunosorbent Spot-forming Assay
FDA Food and Drug Administration
GCP Good Clinical Practice
HSIL High grade squamous intraepi[INVESTIGATOR_360730]-16/18 HPV-16 and/or HPV-18
ICF Informed Consent Form
ICH International Conference on Harmonization -XQ  3URWRFRO _ 9970) _ 
$SSURYHGa
e
gyC iteria  Adveriteria for A
eport
leic Acid
cal Curettage urettage
poration ion 
and Safety MonitorSafety Monitor
lectrocardiogramectrocardiogram
Electronic Case Retronic Case Re
zyme Linkedme L
Link
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.[ADDRESS_449915] Lower Anogenital Squamous Terminology
LEEP Loop Electrosurgical Excision Procedure
LLETZ Large Loop Excision of Transformation Zone
LSIL Low grade squamous intraepi[INVESTIGATOR_018] n
MedDRA®Medical Dictionary for Drug Regulatory Aff rs
MM Medical Monitor
mITT Modified Intent to TreatNILM Negative for intraepi[INVESTIGATOR_360731] i n ePBMC Peripheral Blood Mononuclear Cells
PDC Participant Diary Card
PE Physical Exami on
PHI Protected Health Information
PI [INVESTIGATOR_360732] -XQ  3URWRFRO _ 9970) _ 
$SSURYHGl lesionlesio
gulatory Affairs ory Affai
elial lesion or malign lesion o
of Health alth
djudication Committe ation 
Blood Mononuclearod Mononu
pant Diar Diary CardCard
sical EExamxaminationnation
rotected Health Infootected Health Inf
Principal Investigacipal Investiga
Protocolotoc
Adv
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  84of 8716 REFERENCES
1. Trimble, C.L., et al., Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic
DNA vaccine targeting human papi[INVESTIGATOR_28597] 16 and 18 E6 and E7 proteins for cervical
intraepi[INVESTIGATOR_28601] 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Lancet, 2015. 386 ([ZIP_CODE]): p. 2078-88.
2. Centers for Disease, C. and Prevention, Human papi[INVESTIGATOR_28597]-associated cancers - [LOCATION_002],
2004-2008. MMWR Morb Mortal Wkly Rep, 2012. 61: p. 258-61.
3. Satterwhite, C.L., et al., Sexually transmitted infections among US women and men: prevalence
and incidence estimates, 2008.  Sex Transm Dis, 2013. 40(3): p. 187-93.
4. Hariri, S., et al., Prevalence of genital human papi[INVESTIGATOR_360733],
the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis, 2011. 204(4): p.
566-73.
5. SEER, Surveillance, Epi[INVESTIGATOR_623], and End Results Program National Cancer Institue, 2017.
6. Bruni L, B.-R.L., Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé ICO
Information Centre on HPV and Cancer (HPV Informati  C re). Human Papi[INVESTIGATOR_360734].  2016(Summary Report 15 December 2016.).
7. Guan, P., et al., Human papi[INVESTIGATOR_28597]  n 115,789 HPV-positive women: a meta-analysis
from cervical infection to cancer.  Int J Cancer, 2012. 131(10): p. 2349-59.
8. Apgar, B.S., L. Zoschnick, and T.C. Wr ght, Jr., The 2001 Bethesda System terminology.  Am Fam
Physician, 2003. 68(10): p. 1992
9. McCredie, M.R., et al., Natural history of cervical neoplasia and risk of invasive cancer in women
with cervical intraepi[INVESTIGATOR_28601] 3: a r trospective cohort study. Lancet Oncol, 2008. 9(5):
p. 425-34.
10. McIndoe, W.A., et al., The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol,
1984. 64 (4): p. 451-8.
11. Group, T.F.I.S., Quadrivalent Vaccine against Human Papi[INVESTIGATOR_360735]-Grade
Cervical Lesions. New En land Journal of Medicine, 2007. 356(19): p. 1915-1927.
12. The American College f tetricians and Gynecologists, FAQs Loop Electrosurgical Excision
Procedure (LEEP).  2014.
13. Hirao, L.A., et al., Intradermal/subcutaneous immunization by [CONTACT_360824][INVESTIGATOR_115529].  Vaccine, 2008. 26(3): p. 440-8.
14. Bagarazzi, M.L., et al., Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic
cellular immune responses.  Sci Transl Med, 2012. 4(155): p. 155ra138.
15. Khan, A.S., M.A. Pope, and R. Draghia-Akli, Highly efficient constant-current electroporation
increases in vivo plasmid expression.  DNA Cell Biol, 2005. 24(12): p. 810-8.
16. Diehl, M.C., et al., Tolerability of intramuscular and intradermal delivery by [CONTACT_360825]((R))
adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother,
2013. 9(10): p. 2246-52. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGts Program ogram
M, Gómez D, Muñoz ez D, Mu
PV Information Cent formation C
Report 15 December rt 15 Decem
types in 115,789 Hes in 11
J Cancer, 2012.ncer, 2012. 131(
C. Wright, Jr., right, Jr., The 20
-8.
ral history of cervica story of cer
al neoplasia 3: a retr plasia 3: a
., The invasive poteninvasive poten
-8.8.
Quadrivalent Vaccdrivalent Vacc
New England Jo Eng
o O b sf
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1 
Page  85of 8717. Miettinen, O. and M. Nurminen, Comparative analysis of two rates. Stat Med, 1985. 4(2): p. 213-
26.
18. Stoler, M.H., et al., The accuracy of colposcopic biopsy: analyses from the placebo arm of the
Gardasil clinical trials.  Int J Cancer, 2011. 128(6): p. 1354-62.
19. Xiang, L., et al., Conization Using an Electrosurgical Knife for Cervical Intraepi[INVESTIGATOR_360736].  PLoS One, 2015. 10(7): p. e0131790.
20. Xi, L.F., et al., Risk of cervical intraepi[INVESTIGATOR_190502] [ADDRESS_449916] Dis, 2007.
195(9): p. 1340-4.
21. Katki, H.A., et al., Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS:
performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis, 2013. 
17([ADDRESS_449917] 1): p. S78-84.
22. Nobbenhuis, M.A., et al., Addition of high-risk HPV esting improves the current guidelines on
follow-up after treatment for cervical intraepi[INVESTIGATOR_28601]. Br J Cancer, 2001. 84(6): p. 796-
801.
23. Moore, E.E., et al., Clearance of human papi[INVESTIGATOR_360737].
Obstet Gynecol, 2011. 117(1): p. 101-8. -XQ  3URWRFRO _ 9970) _ 
$SSURYHGPV testing V testing
lial neoplasia. eoplasia. B
pi[INVESTIGATOR_360738] n womvirus in
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 86of 8717 APPENDICES
Appendix A:  GUIDELINES FOR CO LPOSCOPY, BIOPSY, AND SURGICAL 
EXCISION
Colposcopy Procedure
It is recommended that all study colposcopi[INVESTIGATOR_360739] (ASCCP):
1. Use warm, clean water to lubricate the vaginal speculum.  Avoid other lubricant substances which could 
obscure results.
2. If the vaginal walls are lax, a lateral vaginal sidewall retractor aligned perpendicular to the speculum 
may facilitate visualization.
3. Examine the cervico-vaginal secretions and remove any excess mucus from the cervix with saline-
soaked cotton swabs.
4. Obtain any required specimens required for cytology a d HP  t ng.
5. Using low-power magnification (5x to 10 x) inspect h  e v x for obvious areas of abnormalities.
6. Swab or spray the cervix with 3-5% acetic acid.  Reapply every 2-3 minutes during the examination.
7. Use the green or blue filter to examine blood vessels.   magnification (15x)8. Identify the distal and proximal boarders of the transformatio  zone.
a. The inner border is the entire 360-  cumference of the squamocolumnar junction
i. If the junction is proximal to the external os, in the canal, use a cotton-tipped 
applicator to pry either the ante o  ip up or the posterior lip down or use an 
endocervical speculum
ii. If the junction is n  alized in its entire circumference, the colposcopy is 
deemed  inadequ  
b. The distal limit of the transformation zone may be identified by [CONTACT_360826]
9. Inspect the entire new squamocolumnar junction and detect and evaluate any abnormal areas.  
10. Evaluate the upper third portion of the vagina.
11. Lugol or Schiller’s soluti n m  e p ied to further define previously identified lesions.  
Cervical Biopsies 
Endocervical Curettage
ECC is to be performed using a Kervorkian curette or equivalent instrument. Rotate and scrape the curette 360
żin the endocervical canal and use a cytobrush to remove the specimen. Deposit the specimen onto a 
Telfa pad before depositing in the specimen vial containing 10% neutral buffered formalin solution and 
labeled with the subject identification (SID) number.
Ectocervical Biopsies
Ectocervical biopsies should only be performed prior to Week [ADDRESS_449918] lesion should be biopsied in that circumstance.   -XQ  3URWRFRO _ 9970) _ 
$SSURYHGnd HP  testiHPV tes
the cervix for obvi vix for o
eapply every [ADDRESS_449919]
'RZQORDGHG E\ RQ  -XO 
Version Date: 01Jun2022 CONFIDENTIAL Version 4.1
Page 87of 87Surgical Excision
For subjects undergoing surgical excision at the Week 36 visit, the following procedure should be followed:
1. Label each specimen vial containing 10% neutral buffered formalin solution with the SID number and 
the specimen type.
2. Record colposcopy findings from each quadrant according to the following categories
a. Negative (no lesion present)
b. Low Grade  (e.g. pale acetowhite lesion on or off the squamocolumnar junction
c. High Grade  (e.g. dense acetowhite lesion often with mosaic pattern or punctation)
d. Suspi[INVESTIGATOR_360740]
e. Invasive cancer
3. Perform the LEEP, LLETZ or CKC per usual practice.
4. Specimen should be marked at 12 o’clock with suture or gentian violet ink for purposes of orientation.
5. Prepare the biopsy specimen vials for shipment according to the Laboratory Manual. -XQ  3URWRFRO _ 9970) _ 
to t
'RZQORDGHG E\ RQ  -XO 